DISPATCHES FROM THE GUILD CONFERENCE, SERIES #49

A Practical Approach to Integration of Diet and Nutrition in the Management of Patients with IBD

Read Article

Inflammatory bowel diseases (IBD; Crohn’s was anecdotal, there is a growing burden of disease (CD), ulcerative colitis (UC)) are rigorous epidemiologic studies supported by global diseases with a rising prevalence across mechanistic experiments that highlight various several regions of this world.1,2

While changes in several external environmental factors likely contribute to this increase in incidence over the past decade, one such factor that likely plays a central role is the change in diet. Most patients with IBD believe that diet plays an important role in either their disease onset or relapse.3 While previously evidence in support for this was anecdotal, there is a growing burden of rigorous epidemiologic studies supported by mechanistic experiments that highlight various mechanisms through which diet contributes to intestinal inflammation.4-6 Patients also seek to actively incorporate dietary changes in the management of their IBD. It is important for physicians and treating providers to recognize the role diet plays in IBD, familiarize themselves with the various dietary therapies, and develop a practical algorithm to guide patients through this decision process. In this review article, we will summarize the evidence for the role of diet in IBD and present practical tips for integration of dietary therapy in the management of IBD.

Epidemiologic Studies of Diet and Incidence of IBD

Several levels of evidence support a role for dietary changes as being important in the global emergence of IBD. Worldwide, diets have seen a decline in consumption of fiber along with an increase in fatty and sugar-rich diets that derive a significant fraction of their energy from ultraprocessed foods.7 This temporal evolution in dietary practices parallels the rising incidence of IBD, particularly in regions of the world such as Asia and South America that have been more recent venues of such westernization in diet.8 Over the past decade, several rigorously conducted prospective cohort studies from North America, Europe, and low/ middle income countries have provided important signals about the association between diet and the development of IBD.9 In a prospective analysis of 170,776 women enrolled in the Nurses’ Health Study cohorts, women in the highest quartile of intake of dietary fiber had a lower risk of incident Crohn’s disease (hazard ratio (HR) 0.59, 95% confidence interval (CI) 0.39 – 0.90).10 Strikingly, this association was strongest for fiber derived from fruits and vegetables and weaker for insoluble fiber from whole grains and cereals. Dietary fat intake has also been demonstrated to be associated with development of IBD. In both European and North American cohorts, a diet high in n-6 polyunsaturated fatty acids (PUFA) was associated with an elevated risk of ulcerative colitis (odds ratio (OR) 6.09, 95% CI 1.05 – 35.23) while a high n-3/n-6 PUFA ratio was inversely associated with UC risk (HR 0.69, 95% CI 0.49 – 0.98).11,12 There is less consistent data on the impact of a protein rich diet with mixed evidence suggesting an association between animal protein intake or a red-meat rich diet and risk of ulcerative colitis.13 In addition to dietary macronutrients, intake of micronutrients such as vitamin D and zinc, or other food components such as polyphenols, have been hypothesized to modify risk of IBD.14,15 Cohort studies examined the association between dietary patterns and risk of IBD. In the Swedish cohorts, adherence to a Mediterranean diet was associated with a lower risk of older onset Crohn’s disease but not ulcerative colitis (OR 0.42, 95% CI 0.22 – 0.80).16 Western-style diets rich in sugar-rich foods have been associated with increased risk of IBD.17 Hypothesis-driven identification of dietary factors associated with elevated levels of circulation serum inflammatory markers contributing to an Empiric Dietary Inflammatory Potential (EDIP) score was associated with risk of IBD.18 Importantly, the latter study showed diet as a modifiable risk factor in adulthood, demonstrating that a change from a low inflammatory potential to a high inflammatory potential diet was associated with an increase in risk of Crohn’s disease (HR 2.05, 95% CI 1.10 – 3.79). In addition to food constituents themselves, processing of food modified nutritional consult removes certain beneficial components and incorporates additives, emulsifiers, and preservatives to boost taste and preserve shelf-life. A diet rich in ultraprocessed foods was associated with risk of Crohn’s disease both in North America19 as well as in emerging low/middle income countries. In the Nurses’ Health Study cohorts, participants in the highest quartile of energy intake from ultraprocessed foods20 had a two-fold increase in risk of incident CD (HR 1.70, 95% CI 1.23 – 2.35).19

Evidence for Dietary Therapies for the Management of IBD

In contrast to the robust epidemiologic evidence regarding dietary risk factors for IBD, until recently, high-quality evidence for modulation of IBD activity through dietary changes has been sparser.21 The dietary therapy with the strongest evidence behind its efficacy is exclusive enteral nutrition (EEN).22-24 This dietary strategy incorporates exclusion of all table foods while meeting caloric requirements through consumption of either elemental or polymeric formulas. Both types of enteral preparations are similarly effective with the latter being more palatable. In randomized controlled trials, EEN induces clinical remission, normalization of fecal calprotectin and endoscopic healing in Crohn’s disease without evidence supporting its efficacy in UC.25-27 Its efficacy is comparable or only modestly inferior to oral systemic corticosteroids or anti-TNF therapy.25,28 A challenge precluding wider use of this strategy is the difficulty to maintain compliance over the long-term. Partial enteral nutrition (PEN) along with consumption of an unrestricted diet is less effective in achieving resolution of inflammation in CD. However, a strategy of combining PEN with modified exclusion diets that encourage incorporation of dietary fiber and n-3 PUFA while reducing sugar-rich and ultraprocessed foods in the Crohn’s disease exclusion diet (CDED) demonstrated the ability to achieve clinical remission (75% vs. 59%) that was comparable to EEN at 6 weeks and superior to expanding to an unrestricted diet for the subsequent 6 weeks of treatment (75.6% vs. 45.1%, p=0.01).29 A modified version of the CDED that eliminated the use of PEN, relying just on dietary changes was also effective in improving symptoms and resolving inflammation in adult patients with Crohn’s disease.30 Analysis of the initial clinical trial of CDED data showed that response by 3 weeks was a strong predictor of both compliance and clinical improvement. Lack of improvement by 3 weeks in patients who were compliant with the diet was predictive of poor efficacy at the end of treatment. The specific carbohydrate diet (SCD) has gained popularity among patients but supporting evidence of this diet is primarily through case series demonstrating symptom resolution or improvement of calprotectin in some patients.31 The DINE-CD study compared the SCD to a Mediterranean diet in 191 patients with mild to moderately symptomatic Crohn’s disease.32 At 6 weeks, 46.5% of patients in the SCD group and 43.5% in the Mediterranean diet group achieved symptomatic remission (p=0.77). However, only a small fraction of patients in both groups achieved normalization of fecal calprotectin (34.8% vs. 30.8%), highlighting the discrepancy between symptom improvement and objective resolution of inflammation.

Other dietary strategies that have been examined including the autoimmune protocol diet, IBD-anti-inflammatory diet, the IBD-treat diet, an allergy-based diet, a low emulsifier diet, all of which have mixed evidence supporting efficacy primarily from case series without rigorous data on improvement in inflammation.21 In an intriguing strategy incorporating dietary changes along with microbiome-directed therapy, Kedia et al. conducted an RCT of 66 patients with mild-to-moderate ulcerative colitis who received either standard medical therapy or seven weekly colonoscopic infusions of fresh multi-donor FMT and subsequently initiated an anti-inflammatory diet.33 At the end of the clinical trial, the combination of FMT-AID was superior to standard medical therapy in achieving clinical remission (60% vs. 32%) at 8 weeks. The AID was superior to standard medical therapy in maintaining deep remission until 48 weeks (25% vs. 0%).

Practical Tips for Incorporation of Dietary Modification in Management of Patients with IBD

Most gastroenterologists and other treating providers will be asked the question “what can I eat?” by their patient with IBD at some point in the clinical course. The first step in answering that question is to understand the intent of dietary changes (Figure 1). The intent could be to use dietary modification to treat underlying inflammation in IBD, changes to address residual functional symptoms after resolution of inflammation, or to incorporate healthy lifestyle behavior for overall good health. These three aims of the dietary changes merit different answers. For the patient who has residual functional symptoms of diarrhea, abdominal pain, or bloating, despite achieving endoscopic remission of their underlying IBD, dietary strategies can focus on identifying specific dietary triggers of these symptoms and eliminating them from diet. A low FODMAP diet is effective in improving symptoms of abdominal pain and bloating in randomized controlled trials. Trials of lactose-free or gluten-free diets may help identify patients who have lactose intolerance of gluten sensitivity. It is important to ensure that non-culprit food items are re-introduced back in the diet.

For patients who are seeing general good health and reduction in risk of subsequent IBD relapses, a Mediterranean style diet may confer overall health benefits and reduce risk of cardiovascular disease and improve longevity. In addition, mechanistically such diets may be beneficial in preventing IBD relapses though high-quality data on this is lacking. In the absence of stricturing disease, incorporation of sufficient amount of dietary fiber, particularly soluble fiber from fruits and vegetables is important and may be associated with reduced risk of IBD relapses. In addition, minimizing consumption of emulsifier and processed foods is also likely to be beneficial in reducing risk of inflammatory activity. If dietary strategies are being used to achieve remission in symptomatic patients with objective inflammation, it is important to first ensure the patient is appropriate for dietary treatment. Most studies of dietary treatment have focused on those with mild disease activity with paucity of data demonstrating the efficacy of diet for moderate-tosevere disease or those with high-risk phenotypes. Consequently, patients with milder disease can be prioritized for a strategy of dietary modulation. While most studies have focused on diet as the sole treatment, it is reasonable and indeed more acceptable to consider using dietary treatment along with pharmacologic therapy, particularly in those with disease at the more moderate end of the spectrum. The second step is to identify the best dietary intervention based on quality of evidence at that time. Since this is a rapidly evolving field, it is best to identify strategies most supported by high quality data at the time such interventions are being suggested. As for pharmacologic therapy, dietary therapies are effective only if one is able to be adherent to them. Thus, it is important to assess patient motivation, lifestyle, and ability to adhere to diet in deciding the right therapeutic diet for the patient. The third step is to define the right duration of intervention before assessment of outcome. For most dietary studies, the initial phase has been 6-8 weeks long. This is an appropriate duration for a dietary trial with close monitoring for disease worsening. Finally, as for other medical therapies, it is important to ensure objective remission through either biomarkers and/or endoscopic evaluation to ensure that symptom improvement parallels resolution of inflammation. 

In parallel with incorporation of diet, it is important to monitor patient for development of nutritional deficiency either as a consequence of their disease or exclusion diets. It is also important to monitor for the development of avoidant eating disorders in patients relying on diet for treatment of their underlying disease or owing to their symptoms. Multidisciplinary care with a trained dietician is a critically important component for ensuring success of dietary treatment strategies in patients with IBD.

References

  1. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015;12:20517.
  2. Ananthakrishnan AN, Kaplan GG, Ng SC. Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. Clin Gastroenterol Hepatol 2020;18:1252-1260.
  3. Crooks B, McLaughlin J, Limdi J. Dietary beliefs and recommendations in inflammatory bowel disease: a national survey of healthcare professionals in the UK. Frontline Gastroenterol 2022;13:25-31.
  4. Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology 2015;148:1087-106.
  5. Levine A, Rhodes JM, Lindsay JO, et al. Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:1381-1392.
  6. Lewis JD, Abreu MT. Diet as a Trigger or Therapy for Inflammatory Bowel Diseases. Gastroenterology 2016.
  7. Popkin BM. Global changes in diet and activity patterns as drivers of the nutrition transition. Nestle Nutr Workshop Ser Pediatr Program 2009;63:1-10; discussion 10-4, 259-68.
  8. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769-2778.
  9. Khalili H, Chan SSM, Lochhead P, et al. The role of diet in the aetiopathogenesis of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2018;15:525535.
  10. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology 2013;145:970-7.
  11. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease. Gut 2014;63:776-84.
  12. de Silva PS, Olsen A, Christensen J, et al. An association between dietary arachidonic acid, measured in adipose tissue, and ulcerative colitis. Gastroenterology 2010;139:1912-7.
  13. Jantchou P, Morois S, Clavel-Chapelon F, et al. Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study. Am J Gastroenterol
  14. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin d status is associated with reduced risk of Crohn’s disease. Gastroenterology 2012;142:482-9.
  15. Ananthakrishnan AN, Khalili H, Song M, et al. Zinc intake and risk of Crohn’s disease and ulcerative colitis: a prospective cohort study. Int J Epidemiol 2015;44:1995-2005.
  16. Khalili H, Hakansson N, Chan SS, et al. Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn’s disease: results from two large prospective cohort studies. Gut 2020.
  17. Racine A, Carbonnel F, Chan SS, et al. Dietary Patterns and Risk of Inflammatory Bowel Disease in Europe: Results from the EPIC Study. Inflamm Bowel Dis 2016;22:345-54.
  18. Lo CH, Lochhead P, Khalili H, et al. Dietary
    Inflammatory Potential and Risk of Crohn’s Disease and Ulcerative Colitis. Gastroenterology 2020;159:873883 e1.
  19. Lo CH, Khandpur N, Rossato SL, et al. Ultraprocessed Foods and Risk of Crohn’s Disease and Ulcerative Colitis: A Prospective Cohort Study. Clin Gastroenterol Hepatol 2022;20:e1323-e1337.
  20. Narula N, Wong ECL, Dehghan M, et al. Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. BMJ 2021;374:n1554.
  21. Sasson AN, Ananthakrishnan AN, Raman M. Diet in Treatment of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019.
  22. Critch J, Day AS, Otley A, et al. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012;54:298-305.
  23. Day AS, Burgess L. Exclusive enteral nutrition and induction of remission of active Crohn’s disease in children. Expert Rev Clin Immunol 2013;9:375-83; quiz 384.
  24. Kansal S, Wagner J, Kirkwood CD, et al. Enteral Nutrition in Crohn’s Disease: An Underused Therapy. Gastroenterol Res Pract 2013;2013:482108.
  25. Soo J, Malik BA, Turner JM, et al. Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn’s disease. Dig Dis Sci 2013;58:3584-91.
  26. Wall CL, Day AS, Gearry RB. Use of exclusive enteral nutrition in adults with Crohn’s disease: a review. World J Gastroenterol 2013;19:7652-60.
  27. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2007:CD000542.
  28. Lee D, Baldassano RN, Otley AR, et al. Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohn’s Disease. Inflamm Bowel Dis 2015;21:1786-93.
  29. Levine A, Wine E, Assa A, et al. Crohn’s Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology 2019;157:440-450 e8.
  30. Yanai H, Levine A, Hirsch A, et al. The Crohn’s disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn’s disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol 2022;7:49-59.
  31. Suskind DL, Wahbeh G, Gregory N, et al. Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. J Pediatr Gastroenterol Nutr 2014;58:87-91.
  32. Lewis JD, Sandler RS, Brotherton C, et al. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn’s Disease. Gastroenterology 2021;161:837-852 e9.
  33. Kedia S, Virmani S, S KV, et al. Faecal microbiota transplantation with anti-inflammatory diet (FMTAID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial. Gut 2022.

Download Tables, Images & References

NUTRITION REVIEWS IN GASTROENTEROLOGY, SERIES #1

Exclusive Enteral Nutrition in Inflammatory Bowel Disease: An Under-Appreciated Therapeutic Gem

Read Article

Patients with inflammatory bowel disease (IBD) experience periods of disease flares and remission throughout their lives. Despite advances in medical therapy that provide increasing treatment options to help patients achieve and maintain remission, complementary diet strategies can work synergistically to improve the clinical course in IBD. Exclusive enteral nutrition (EEN) is a nutritional therapy that has shown promise as a low-risk therapeutic approach to improve symptoms and reduce inflammation, with the potential to heal gut mucosa, heal fistulas, and decrease perioperative complications, all while providing nourishment to the individual. Current underutilization of EEN in the clinical setting may be related to a myriad of factors, including lack of provider awareness and experience, insufficient support staff, or assumed high rate of non-adherence. The aim of this review is to discuss the evidence supporting EEN in adults with IBD and provide practical suggestions for the implementation of this nutritional therapy.

INTRODUCTION

Inflammatory bowel diseases (IBD) are chronic diseases for which there are no known cure. The two main subtypes of IBD include Crohn’s disease (CD) and ulcerative colitis (UC). Individuals with IBD experience periods of disease flares and remission throughout their lives and are commonly managed with medications, which have become increasingly effective for inducing and maintaining remission.

A significant subset of patients does not adequately respond to medical therapies, and it is not uncommon for patients to experience a loss of therapeutic response over time. Further, medications that are traditionally used to induce rapid reduction in symptoms or remission, such as corticosteroids, come with significant potential side effects that increase with long-term use. The European Society of Parenteral and Enteral Nutrition (ESPEN) guidelines for IBD recommend the use of Exclusive Enteral Nutrition (EEN) as primary therapy for inducing remission in pediatric Crohn’s disease, and in adults when steroids are not tolerated or are contraindicated.1

When used as adjunctive therapy, nutritional therapeutics can work synergistically to improve the clinical course in IBD by nourishing the patient, while also reducing symptoms, decreasing inflammation, and synergistically augmenting response to medical therapy. An increasing number of studies in adults with IBD suggest that EEN shows promise as a low-risk therapeutic agent with the potential to not only improve symptoms, but to also reduce inflammation, and even to heal both gut mucosa and fistulas, as well as to decrease perioperative complications. Despite the evidence supporting EEN’s potential benefits, current underutilization in both the inpatient and outpatient clinical settings may be related to a myriad of factors, including lack of clinician awareness and experience, insufficient support staff, or assumed high rate of non-adherence.

What is EEN?

EEN is a nutritional therapy that involves consuming a complete nutrition liquid formula as a sole source of nutrition for 1-12 weeks. Formula is usually taken by mouth but can also be infused via enteric tube. The type of formula and duration of therapy depends on the indication for use, patient history, allergies, budget, tolerance, taste and ingredient preference, and availability. See Table 1 for a list of complete nutrition formula options that are commercially available.

The wider variety of formula flavors and compositions, including more organic and vegan options has improved patient acceptance and preference. Formula types that are available include: polymeric (whole, intact proteins), semielemental (hydrolyzed proteins) and elemental (free amino acids). The more palatable polymeric formulas are effective for induction of remission, but patients with allergies, impaired absorption, or prior resections may require a semi-elemental or elemental formula.

Shorter durations of EEN can be used to reduce clinical symptoms or for nutritional optimization in preparation for planned surgery; longer durations are needed to induce endoscopic and histologic remission and healing gut mucosa. EEN has historically been used in children and adolescents with Crohn’s disease, and although its efficacy has been demonstrated in adults, EEN is underutilized as an adjunctive therapy. While the experience with EEN in UC is emerging, to date there remains a paucity of literature for its potential roles in UC management.

EEN for Induction of Remission

Corticosteroid therapy has traditionally been used to induce remission in active IBD. While often effective, the short- and long-term side effects, including hyperglycemia, fluid retention, changes in mood, insomnia, hypertension, glaucoma, cataracts, osteoporosis, avascular necrosis, and effects on wound healing and body distortion such as rapid weight gain, moon facies and stretch marks remain a concern to patients and providers, so reducing exposure to corticosteroids is

imperative. EEN provides an opportunity to limit steroid exposure, and has the added benefits of nourishing the individual, correcting dysbiosis seen in active disease, decreasing inflammatory cytokine production, and promoting mucosal healing.2 EEN can be particularly beneficial for those desiring to avoid steroids, those who are intolerant to steroids, and those who are pregnant.

EEN has been predominantly studied in pediatric Crohn’s disease, where durations of therapy of 6-12 weeks have demonstrated remission (clinical and potentially biochemical, endoscopic, radiologic) in up to 80% of cases.3 While the mechanics of EEN are thought to be the same in adults, a recent Cochrane meta-analysis found EEN was slightly less effective than steroids for remission induction in adults with Crohn’s disease.4 It is important to consider the studies used for this meta-analysis were of low quality and had a high rate of non-adherence to EEN.5 Low adherence and underutilization are likely multifactorial and may be due to palatability of formula, lack of insurance coverage, lack of knowledgeable support staff, and lack of training, experience, and conviction of efficacy among providers. A recent prospective study of children and adults on EEN, mucosal healing was reported in 79% of patients on EEN for an average of 123 days (range 50-212 days).6 Thus, emerging evidence supports the role of EEN as a very safe, effective option for primary induction therapy for adult Crohn’s disease patients who are flaring.

While the literature surrounding the effectiveness of EEN in pregnancy is limited, a recent retrospective study demonstrated the potential to achieve clinical remission in patients with Crohn’s disease who were pregnant and consumed a peptide-based EEN formula for 12 weeks.7 A recent randomized controlled trial of 62 adults hospitalized for acute severe ulcerative colitis flares found that 7 days of EEN using a semielemental formula augmented response to steroids, reduced hospital length of stay, and resulted in reduced colectomy and re-hospitalization at 6 months compared to those who received standard of care.8 That being said, there remains a paucity of published evidence for the potential roles of EEN in UC.

It should be acknowledged that replacing food with formula exclusively can be too challenging for some patients to implement in real life. Thus, it is important to recognized that evidence suggests that even partial enteral nutrition (PEN) strategies (formula combined with foods) may be effective as a combination therapy along with biologics for inducing and maintaining remission in patients with Crohn’s disease. A meta-analysis of four studies in adults with Crohn’s disease (n=342) found the PEN approach as combination therapy with a biologic (infliximab) resulted in 69% of patients achieving clinical remission versus 45% on a biologic as monotherapy. The study authors pointed out that that amounts to over a 2-fold increase in the odds of achieving clinical remission amongst patients on combination therapy with PEN added to infliximab compared with those on infliximab monotherapy alone. Further, 74% on infliximab/ PEN combination therapy remained in clinical remission at one year, compared to 49% of those on infliximab monotherapy and the probability of maintaining clinical remission on combination therapy appeared to extend beyond 1 year.9

EEN and Fistulizing Disease

A severe complication of Crohn’s disease includes fistula formation. A fistula is an abnormal connection between the gut and another organ (e.g., bladder, vagina, skin, or other part of the intestinal tract). In IBD, fistulas can form as a result of inadequately treated inflammation. Medical therapy traditionally involves starting or adjusting immunosuppressive/ biologic medications, surgery, and/or local control with the placement of setons (flexible tubing or material inserted within the fistula tract that keeps the fistula open to allow it to drain). Studies investigating EEN in patients with Crohn’s disease demonstrate high rates of remission and fistula closure after 4-12 weeks of EEN therapy. A single-center prospective study (n=41) of patients with entero-cutaneous fistulas (ECF) found 80% achieved full clinical remission and 75% had fistula closure after 12 weeks on EEN.10 Another study (n=48) found similar rates of ECF closure at 62% after 3 months on EEN using a semi-elemental formula, with an average fistula closure time around 32 days. Additionally, they found improvements in nutrition with increases in weight, BMI, and hemoglobin, and identified lower baseline CRP and higher baseline BMI as predictors of response to EEN.11

EEN in Elective Surgery

A recent meta-analysis of contemporary studies found a 5-year cumulative risk of surgery of 7% in UC and 18% in Crohn’s disease.12 Importantly, in patients heading towards surgery malnutrition is frequently identified and increases the risk for post-op complications and mortality. Therefore, clinical guidelines recommend nutrition support for optimization perioperatively in those with weight loss >10% in 6 months, BMI <18.5 kg/m2, or an albumin of <3 g/dL, and delaying surgery for 7-14 days if feasible to allow for nutrition optimization.1 Administration of EEN 4-6 weeks perioperatively may serve as a tool to improve nutrition status pre-operatively, decrease inflammation, improve post-operative outcomes, and a small, but significant subset of patients may even be able to avoid surgery when treated with perioperative EEN. The latter was highlighted by a retrospective study (n=51) of adult patients with complicated Crohn’s disease in which 25% of patients who received EEN as part of their preoperative management for an average of 6 weeks were able to avoid surgery. In those who proceeded with surgery, there was a significant decrease in length of time in the operating room, anastomotic leak, and abscess formation.13 The positive findings from this study are limited by the design (retrospective, single center, small study population). Another single center study (n=87) found 4 weeks of EEN taken via naso-gastric tube decreased risk for surgery over a 2-year follow-up period in adult patients with Crohn’s disease and intra-abdominal abscess compared to those who received standard care (26% vs. 56%, p=0.01).14 Furthermore, a meta-analysis found pre-op EEN significantly reduced post-operative complications compared to those who did not receive EEN (21% vs. 73%, p<0.001), with a number needed to treat of 2.15 While larger, prospective trials are needed to confirm these results, these studies do highlight the use of EEN as a promising potentially effective tool to improve surgical outcomes.

PRACTICAL APPLICATIONS
Commencement of EEN

The primary reason EEN is not used as widely in adults is the lack of multidisciplinary support. Many, if not most, gastroenterologists and surgeons who care for adult patients with IBD are not well-educated on the potential benefits of enteral nutrition, nor are convinced of its potential efficacy, and few have the experience to effectively initiate, guide, and monitor patients on EEN. Optimizing success with EEN therapy involves much more that writing a prescription for EEN. A registered dietitian (RD) who is experienced in IBD and experienced with EEN is a vital member on the care team who can provide a comprehensive nutrition assessment and guide patients who are appropriate for and desire EEN as therapy (see Figure 1 for an EEN algorithm). Small studies suggest that adult patients with IBD do not have increased energy requirements above the general population, therefore standard predictive equations (e.g., Mifflin St. Jeor) can be used when estimating nutrition needs.1 Importantly, additional calories may very well be needed to assist with wound healing, perioperative needs, or weight gain. Similarly, while protein needs are comparable to the general population in quiescent disease (1 gm/kg), they are increased during active disease (1.2-1.5 grams/kg) due to increased proteolysis, enteric losses, or effects of disease treatments such as corticosteroids.1

Ideal candidates for EEN include not only those who are malnourished, but also those motivated patients with active disease, disease complications (e.g., fistulas, strictures), those who are planning for potential surgery, and those desiring to limit corticosteroid exposure (e.g., those intolerant or non-responsive to corticosteroids, or those who are pregnant). It is also important to consider psycho-social factors, as EEN can be cognitively and emotionally demanding. Researchers found that those with greater levels of conscientiousness were more adherent to therapy.16 Access to a social worker,psychologist and/or psychiatrist – ideally as part of the multidisciplinary IBD team, or at least familiar with IBD – is important for supporting patients during disease flares and may help with successful completion of EEN therapy. Once a nutrition prescription has been developed, the next step in initiating EEN is to choose a formula. Consider nutrition content, cost, availability, allergies/intolerances, medical/ surgical history (length of functional intestine remaining), palatability, and patient preference when selecting a formula. It may be beneficial for patients to try multiple formula options before deciding on which to use for their EEN treatment, as palatability, tolerance, and cost are important

factors for adherence. Some patients desire organic formulas or formulas with less sugar, and some desire concentrated formulas to allow nutrient needs to be met in a smaller volume. Formulas for EEN are not often covered by insurance companies but writing a prescription along with a letter of medical necessity can increase the odds of formula coverage. This is important for the patient to know upfront so they can determine if EEN is an affordable therapy in the event they must pay out of pocket. The cost of formulas vary; with standard 1 kcal/mL formulas being the most cost-effective and concentrated or semi-elemental or elemental being the most expensive (see Table 1 for commercially available formulas). When discussing the cost of EEN or PEN therapy, it can be helpful to point out that the formula will be replacing what they would normally spend on meals, snacks, and beverages consumed at home or when eating out. During the initial consultation, the patient should receive instruction on the anticipated duration of EEN, which will be determined by the indication for use. The route of administration can be oral or via a small diameter flexible enteric feeding tube (self-inserted or inserted by staff). Monitoring patients on EEN may include weekly update on weight and symptoms, and periodic labs or stool tests to monitor disease activity and nutrition status (e.g., chemistry panel, c-reactive protein, sedimentation rate, fecal calprotectin, iron studies and complete blood count, zinc, vitamin D (25-OH), vitamin B6).

After selecting a formula, the patient should be provided with instruction on how to start EEN. If the patient regularly consumes caffeine, he or she may want to wean off caffeine in the days before starting EEN to avoid caffeine-withdrawal symptoms. While there is no consensus on how to start EEN, a gradual transition onto EEN over a few days may help with tolerance (e.g., replace one meal each day with 2-3 formula shakes until completely on EEN and off solid foods). This approach would also be recommended if the patient is severely malnourished or at high risk for refeeding syndrome.

Encourage strict adherence to EEN (no other food or beverage except water), as efficacy decreases with exposure of other foods and beverages. Patients should be advised to stop all other nutrition supplements (e.g., multivitamin, calcium) as the nutrition formulas are considered “complete” and fortified, usually providing 100% of the recommended dietary allowance in about 1 liter.

Clinical symptoms, such as bloating, pain, diarrhea, urgency, constipation, may occur during the transition period off food and onto EEN, thus patients should be reassured that such symptoms should subside and improve within 1-2 weeks. Drinking the formula slowly (over 30-60 minutes) and spacing the formula out throughout the day can help with tolerance. If symptoms persist at two weeks, consider alternate formula or alternate route of administration (e.g., small bore nasogastric feeding tube) or alternate therapy. Hydration is important to emphasize. To optimize tolerance and success, patients who struggle with any aspect of EEN should be encouraged to contact their RD for support and guidance as issues arise. At our center, patients are given instructions to provide weekly updates to the RD through a secure patient portal to ensure the patient is tolerating EEN, weight goals are met, symptoms are improving, and that EEN remains an appropriate treatment. The weekly patient updates allow the RD to intervene early if changes to the treatment plan are needed, such as increases in formula volume goal to support weight gain, or to provide support if patients are having difficulty implementing EEN at home or in social settings.

Navigating Life on EEN

Relying on a liquid diet as a sole source of nutrition for weeks at a time can be emotionally and cognitively challenging. Eating food is how we nourish our bodies, both physically and emotionally. The ritual of eating plays a large part in how we experience cultures, celebrate with friends, socialize with colleagues, connect with family, and grieve. Acknowledge the impact EEN will have on patients. For some, EEN may feel isolating. For others, EEN may be liberating by allowing them to be more active and social because the symptoms they had been experiencing prior to EEN are improved by EEN.

With the reduction in inflammatory cytokines, mucosal healing, and the full nourishment of the patient, an increase in quality of life is to be expected. Patients should be encouraged to engage in activities that bring them joy (e.g., hiking, biking, swimming, going to the beach, seeing family or friends). If activities involve food, it may be best to arrive full (drink shakes beforehand) or bring shakes to the event to allow nourishment at the same time others are eating and drinking.

The formulas can become monotonous in both flavor and texture. Encourage patients to choose different flavors of formula to help decrease monotony. Mixing flavors (chocolate, vanilla) can also provide a little extra variety. Some find freezing formula in ice cube trays to blend with formula from the can is a fun way to add different texture. Other creative options include freezing formula in popsicle molds to serve as a cool treat on a hot day, or warming chocolate formula in a mug can provide some soothing comfort on a cold night. Some formulas can be difficult to purchase from the store and transport home. Writing a prescription for EEN and connecting the patient with a home health company may help increase the odds that the formula will be covered, all or in part, by their insurance. Additionally, patients will receive supplies of formula shipped directly to their home, ensuring they have enough formula for their EEN. In our center, we also provide travel letters to patients who will be going through security checkpoints. This allows them to carry their formula with them during their travels instead of having to go without.

Transitioning from EEN

EEN is not a sustainable long-term therapy for most individuals. There is a lack of evidence to recommend an evidence-based specific strategy for food reintroduction after EEN. Discussions about how to transition off EEN can happen at any point during the patient’s journey but should commence prior to the end date for EEN.

A single center study in pediatric patients with Crohn’s disease found no difference in rates of clinical remission at 12 months with a gradual food reintroduction over 5 weeks versus rapid reintroduction of food over 3 days.17 While this study was done in children and not adults, it provides some reassurance that a rapid food reintroduction doesn’t worsen disease outcomes and may be the best approach, as long and drawnout food reintroductions may result in inadequate intake, weight loss, or nutrient imbalances. It may be prudent to advise patients to start with small portions of low fat and well-cooked foods (see Table 2 for examples) to assist with tolerance when initially re-introducing foods.

Research suggests specific diet therapies may assist with maintenance of remission; these include adoption of longer-term PEN, a semi-vegetarian diet, or a diet that follows guidelines from the International Organization of the Study for IBD (IOIBD); it is beyond the scope of this article to review these diets. Thus, transitioning from EEN to such an adjunctive nutritional strategy should be considered beyond just maintenance medicinal strategies alone. Regardless of the strategy, a follow-up visit with the RD a few weeks before stopping EEN or after starting foods is recommended to ensure diet balance and tolerance.

Conclusion

EEN is a safe and effective therapy for IBD with the potential to induce clinical, endoscopic, and histologic remission, heal fistulas, and when used perioperatively, to improve nutrition status and surgical outcomes, while avoiding steroid side effects. While most studies have shown the benefit of EEN in pediatric IBD, an increasing number of small studies and meta-analyses show benefits in the adult population as well. EEN is currently underutilized and should be considered in patients as an adjunctive therapeutic tool in the expanding treatment armamentarium. Thoughtful implementation of EEN guided by and supported by the multidisciplinary IBD team is likely to maximize adherence and therapeutic success.

References

  1. Bischoff SC, Escher J, Hebuterne X, et al: ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. Clin Nutr 2020;39(3):632-653.
  2. Mitrev N, Huang H, Hannah B, et al: Review of exclusive enteral therapy in adult Crohn’s disease. BMJ Open Gastroenterol 2021;8(1):e000745.
  3. Ashton J, Gavin J, Beattie M: Exclusive enteral nutrition in Crohn’s disease: Evidence and practicalities. Clin Nutr 2019;38(1):80-89.
  4. Zachos M, Tondeur M, Griffiths A. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev 2007;24(1):CD000542.
  5. Wall CL, Day AS, Gearry RB: Use of exclusive enteral nutrition in adults with Crohn’s disease: a review. World J Gastroenterol 2013;19(43):7652-7660.
  6. Chen JM, He LW, Yan T, et al: Oral exclusive enteral nutrition induces mucosal and transmural healing in patients with Crohn’s disease. Gastroenterol Rep (Oxf) 2019;7(3):176-184.
  7. Yang Q, Tang J, Ding N, et al: Twelve-week peptidebased formula therapy may be effective in inducing remission of active Crohn disease among women who are pregnant or preparing for pregnancy. Nutr Clin Pract 2022;37(2):366-376.
  8. Sahu P, Kedia S, Vuyyuru SK, et al: Randomized clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. Aliment Pharmacol Ther 2021;53(5):568-576.
  9. Nguyan DL, Palmer LB, Nguyen ET, et al: Specialized enteral nutrition therapy in Crohn’s disease patients on maintenance infliximab therapy: a meta-analysis. Therap Adv Gastroenterol 2015;8(4):168-175.
  10. Yang Q, Gao X, Chen H, et al: Efficacy of exclusive enteral nutrition in complicated Crohn’s disease. Scand J Gastroenterol 2017;52(9):995-1001.
  11. Yan D, Ren J, Wang G, et al: Predictors of response to enteral nutrition in abdominal enterocutaneous fistula patients with Crohn’s disease. Eur J Clin Nutr 2014;68:959–63.
  12. Tsai L, Ma C, Dulai PS, et al: Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn’s Disease: A Meta-Analysis of Population-Based Cohorts. Clin Gastroenterol Hepatol 2021;19(10):2031-2045.
  13. Heerasing N, Thompson B, Hendy P, et al. Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn’s disease. Aliment Pharmacol Ther 2017;45:660–9.
  14. Zheng X-B, Peng X, Xie X-Y, et al: Enteral nutrition is associated with a decreased risk of surgical intervention in Crohn’s disease patients with spontaneous intra-abdominal abscess. Rev Esp Enferm Dig 2017;109:834–42.
  15. Brennan GT, Ha I, Hogan C, et al: Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn’s disease patients: a metaanalysis. Eur J Gastroenterol Hepatol 2018;30:997– 1002.
  16. Wall CL, McCombie A, Mulder R, et al: Adherence to exclusive enteral nutrition by adults with active Crohn’s disease is associated with conscientiousness personality trait: a sub-study. J Hum Nutr Diet 2020;33(6):752-757.
  17. Faiman A, Mutalib M, Moylan A, et al: Standard versus rapid food reintroduction after exclusive enteral nutritional therapy in paediatric Crohn’s Disease. Eur J gastroenterol Hepatol 2014;26(3):276-281.

Download Tables, Images & References

INTRODUCTION: NUTRITION REVIEWS IN GASTROENTEROLOGY

Nutrition Reviews in Gastroenterology The Series: An Homage and a Transition

Read Article

Over the years, the series, Nutrition Issues in Gastroenterology, has been a valuable resource for reviews of current evidencebased research in gastrointestinal (GI) nutrition. The series has elevated the status of, and attention to, medical nutrition therapies for GI disorders. One might argue that it has fostered the growth of GI/Nutrition as a discipline for physicians and dietitians alike. The series has solidified that nutrition has an essential place in the literature to advance nutrition research, education, and practice in gastroenterology.

The founding editor, Carol Rees Parrish, MS, RD, has built a library from the series. Since 2003, over 200 articles have been published in the Journal of Practical Gastroenterology. We are thankful for her passion, dedication, and diligence towards the series that has served to counteract misinformation and give practical applications to integrate into clinical practice. Through the years, Carol Rees Parrish, MS, RD has recruited countless interdisciplinary authors to contribute their knowledge and nutrition expertise on a variety of topics. It takes a village!

Starting January 2023, the baton will pass and so begins a new era of the Practical Gastroenterology Nutrition Series. As the new editors for the series, now called Nutrition Reviews in Gastroenterology, we will continue to strive to publish evidencebased nutrition reviews to provide updates for clinical practice. We look forward to our new role.

We welcome your ideas. If there are GI-related nutrition topics of interest to the readers of Practical Gastroenterology, please contact the series editors, Neha D. Shah MPH, RD, CNSC, CHES at neha@nehashahnutrition.com and Elizabeth Wall, MS, RDN-AP, CNSC at Elizabeth.Wall@uchicagomedicine.org.

Thank you for your ongoing support for the series.

Download Tables, Images & References

MEDICAL BULLETIN BOARD

Liver Health Initiative Working Toward Eliminating Hepatitis

Promoting Liver Health Education. Our Passion is Prevention. Health programs and efforts to inform the public about the importance of sharing liver education can play a major role in prevention as well as patient care.

January 3, 2023 – Health programs and efforts to inform the public about the importance of sharing liver education can play a major role in prevention as well as patient care.

Despite major advances and extensive awareness campaigns being promoted to encourage testing for hepatitis, we’re very far from reaching elimination targets. Many barriers exist including poor access to prompt testing, persistently high costs of treatment, and ultimately, lack of awareness about the need for testing and treatment.

One study out of Kentucky is attempting to make headway by utilizing diagnostic methods for on-the-spot testing with rapid results in approximately one hour after a finger prick. This can significantly improve testing opportunities, and if coupled with immediate treatment, we have greater odds of reaching difficult to reach vulnerable populations.

However, this new effort to fortify testing does not negate the power of public education and awareness.

A vitally important component that has been glaringly absent in current efforts to eliminate hepatitis B and hepatitis C has been education about the liver itself. Most people have little to no knowledge of how important their noncomplaining liver is, how it is damaged by hepatitis viruses or how to protect it from harm. Tragically, they are unknowingly participating in liver damaging activities including those that expose them to hepatitis viruses that infect their liver and its miraculous life supporting liver cells.

Awareness campaigns have tried for several years to encourage people to be tested for silent or undiagnosed hepatitis that affects an organ they know little or nothing about. This issue is deterring screening and testing, as well as treatment initiation and compliance.

Addressing this issue, hepatitis, and other liver related diseases including obesity and cancer, the Liver Health Initiative (LHI) has made information about complex liver functions understandable, personal and even entertaining using memorable analogies and story-telling techniques. These communication techniques empower individuals to act on information provided.

Prominent institutions including Virginia Commonwealth University Medical School, Johns Hopkins University Medical School and Bloomberg School of Public Health, University of Illinois, The Carle Illinois Medical School, and University of North Texas Health Sciences Center among others have adopted LHI’s approach and Foundation for Decision Making teaching tools to enhance their health education programs and efforts to inform their audiences about the importance of communicating liver health information to patients and the public as well.

Currently, information about the liver is absent in schools and most hepatitis agencies and programs. Although two research studies confirm the effectiveness of liver health education in motivating individuals to avoid liver damaging behaviors, children and adults are being denied information about the liver. The National Academy of Sciences requires additional studies to be conducted to provide a stronger foundation for integrating this approach broadly in interventions to address hepatitis and other liver diseases.

While working hard to develop a long-awaited vaccine against hepatitis C, Sir Michael Houghton,

PhD, Nobel Laureate and member of LHI Board of Directors said, “These understandable and memorable liver related communication techniques enhance efforts to empower patients to seek testing for hepatitis and other liver diseases. An initiative that is long overdue.”

For further information, visit us at:

Thelma King Thiel, Chair Liver Health Initiative

Email: livrlady@gmail.com

Twitter: @the_liver_lady

Download Tables, Images & References

DISPATCHES FROM THE GUILD CONFERENCE, SERIES #48

The Overlooked Symptoms of Cirrhosis

Read Article

Cirrhosis is increasingly common and morbid. While contemporary care often focuses on the classic complications of cirrhosis, the overlooked symptoms of cirrhosis pose a great toll on patient well-being. These symptoms include muscle cramps, itching, sleep disorder, falls, sexual dysfunction, itching, and chronic pain. This review aims to provide a practical way of addressing the symptoms of cirrhosis with the aim of enriching quality of life for those living with cirrhosis.

Cirrhosis is common and morbid. Its prevalence addressing the symptoms of cirrhosis with the aim exceeds >1 million persons in the United of enriching quality of life for those living with States (US) alone,5 rising by 50% in the past cirrhosis. Recommendations are summarized in 20 years.6 There has been substantial progress in the early detection and supportive care for cirrhosis. While contemporary care often focuses on screening for and managing the complications of cirrhosis such as hepatocellular carcinoma, varices, ascites, and hepatic encephalopathy (HE), the overlooked symptoms of cirrhosis take a great toll on patient well-being.7 These symptoms include muscle cramps, sleep disorder, falls, sexual dysfunction, itching, and chronic pain. It is recognized that the identification and management of these symptoms is part of high-quality care.1-4 This review aims to provide a practical way of addressing the symptoms of cirrhosis with the aim of enriching quality of life for those living with cirrhosis. Recommendations are summarized in Figure 1.

Pruritus

Patients with cholestatic liver disease can experience profound itching.8 Patients with noncholestatic liver disease also experience bothersome itching, however the evidence supporting specific interventions is often lacking for these patients. Pruritus can be screened with the question “How much of the time have you been troubled by itching during the last two weeks?”, after which its severity can be assessed using a visual analog scale. The mechanisms of itch in cirrhosis are varied and involve dry skin, increased pruritogens (known, like bile salts, or unknown), and increased itch perception or catastrophizing. For this reason, treatments address each step in this conceptual model of pruritis.8 Pharmacotherapeutic options for cholestatic pruritus that have been tested in clinical trials include bile acid binders cholestyramine (48g BID-QID),9 colesevelam (2-8g BID),10 rifampin (150-300mg BID),11,12 naltrexone (50mg daily),13-15 sertraline (25-100mg daily),16 and bezafibrate (can be replaced with fenofibrate, 100-145mg daily).17,18 These therapies are often ineffective in noncholestatic cirrhosis. A prudent clinical strategy is to identify bothersome itch, counsel on the importance of frequent whole-body moisturizing, and cautiously utilize therapies for patients with persistent unmet needs.

Muscle Cramps

Muscle cramps are common in cirrhosis, impacting 1 in 3 patients and causing poor health-related quality of life.19-21 Muscle cramps can be identified by asking “During the past month, how many painful muscle spasms, cramps, or charley horses have you had? Do they bother you?” Thereafter, the severity of muscle cramps should be assessed using a visual analog scale. Pharmacological treatments for muscle cramps in patients with cirrhosis include taurine (1g TID),22 quinidine,23,24 and sips of pickle juice at cramp onset.25 The largest trial enrolling patients with cirrhosis in the US is the PICCLes trial. Upon contact with the oropharynx, the ascetic acid triggers a nerve reflex that aborts the muscle cramp. Though pickle brine has sodium, only 1 tablespoon (~25mg sodium) is required. Compared to a tap water control, sips of kosher or dill pickle brine at cramp onset were more likely to abort the muscle cramp and reduce cramp severity. This intervention did not reduce the frequency of muscle cramps. For this reason, if short-duration, high frequency cramps are the patient’s problem, a trial of taurine may be reasonable.

Sexual Dysfunction

Sexual dysfunction impacts 53%-93% of patients with cirrhosis.19 Sexual satisfaction can be assessed with the questions: Have you had any sexual activity in the past few weeks? How satisfied were you with your sexual function during the past few weeks? Patients who report dissatisfaction who are smoking should be counselled that smoking interferes with sexual function and cessation therapy should be considered. Comorbid depression should be assessed, and care initiated if present. Finally, if the patient is consuming alcohol, abstinence should be recommended with assistance from psychotherapy or pharmacotherapy. Sexual function improves with freedom from alcohol and this expectation can be used when counseling patients.26 A randomized controlled trial of tadalafil safely enhanced erectile function along with improved depression, anxiety, and quality of life compared to placebo.27 Similar results may be seen from sildenafil but this has not been trialed. Testosterone has been trialed and is a promising therapy for men with low testosterone without HCC or prostate cancer who have been counselled regarding cardiovascular risks.28 It may also improve frailty and sarcopenia. There have been no clinical studies of pharmacological treatments for female sexual dysfunction in patients with cirrhosis.29 Vaginal dryness can be queried and addressed with personal lubricants. For postmenopausal women, a trial of topical vaginal estrogen can be helpful. In patients who experience recurrent urinary tract infection, vaginal estrogen can significantly reduce recurrence rates.30

Sleep Disturbances

Sleep disturbances, which include sleepwake inversion, excessive daytime sleepiness, and insomnia, affect 50-80% of patients with cirrhosis.19,31-33 Sleep quality can be assessed with the following question “During the past month, how would you rate your sleep quality overall?” (graded with a 5-point Likert scale from Very Good to Very Bad). Sleep quality can be poor if sleep hygiene is poor, or the patient has sleep apnea. These things can be addressed in parallel with considering the influence of cirrhosis with factors including muscle cramps and HE. Treatment of HE may help to improve sleep disturbances in patients with cirrhosis.34,35 Minimal HE can be identified with using the EncephalApp.com or the animal naming test. Short courses of melatonin (1-3mg), zolpidem, and hydroxyzine (25-50mg) have also been shown to improve sleep quality in randomized trials of patients with Child Pugh A and B cirrhosis.36-38 However, zolpidem should be avoided as it increases the risk of falls and fractures.39,40

Falls

Falls are common. The probability of falls among patients without prior HE was 28.8% and 50.2% at 1 and 3 years.4 HE is likely an even stronger risk factor. The CDC recommends screening for falls among those older than 65 by asking about falls within the past 6 months. However, cirrhosis is a risk factor for falls and falls occur at younger ages in cirrhosis. As such, screening may be beneficial. Interventions should be focused on eliminating as many risk factors as possible in each individual patient. Evidence-interventions include HE-directed therapy for those with cognitive dysfunction, tai chi, exercise programs, and reduction of polypharmacy, particularly hypnotics like zolpidem.41

Pain

Chronic pain is a challenging comorbidity in the management of cirrhosis. Pain is common – cramps, symptomatic ascites, injurious falls with fractures – and its management is complicated by a narrow therapeutic index related to cirrhosis physiology. For example, nonsteroidal antiinflammatory medications can cause renal injury and worsened ascites and opioids can cause constipation, precipitating HE. The management of chronic pain benefits first from an accurate classification of pain: nociceptive (bodily injury), neuropathic, and nociplastic. Nociplastic pain is typically widespread and features no evidence of tissue or nerve damage such as fibromyalgia or irritable bowel syndrome. Nociceptive pain should be managed with low dose (maximum 2000mg daily) acetaminophen, topical therapy (e.g., topical diclofenac), or low dose opioids for acute pain such as fractures, provided that constipation is proactively avoided. Neuropathic pain can be treated with topical therapy (e.g., capsaicin, lidocaine), local injections if amenable, or tricyclic antidepressants. Nociplastic pain benefits from a holistic approach including addressing sleep disorder and mood disorder and promoting physical and mindfulness activities prior or in addition to any pharmacologic interventions.42

Conclusion

The overlooked symptoms of cirrhosis are common, morbid, and matter to patients. There are simple, quick ways to screen for these symptoms. Each symptom, furthermore, can be improved with evidence-based therapies and approaches. In many cases, first-line therapies may not prove effective. However, patients will appreciate the attention to a distressing problem after which stepwise, multidisciplinary care can deliberately trial supportive therapies. The expectation is not that these recommendations will solve all symptoms – though in some cases they will – but rather that patient’s well-being becomes of focus of their clinical care.

References

  1. Kanwal F, Tapper EB, Ho C, et al. Development of quality measures in cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2019;69:17871797.
  2. Tapper E, Kanwal F, Asrani S, et al. Patient Reported Outcomes in Cirrhosis: A Scoping Review of the Literature. Hepatology (Baltimore, Md.) 2017.
  3. Asrani SK, Ghabril MS, Kuo A, et al. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022;75:12891299.
  4. Serper M, Parikh ND, Thiele G, et al. Patientreported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022.
  5. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-8.
  6. Mellinger JL, Shedden K, Winder GS, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology 2018;68:872-882.
  7. Foster C, Baki J, Nikirk S, et al. Comprehensive Health-State Utilities in Contemporary Patients With Cirrhosis. Hepatology Communications 2020.
  8. Beuers U, Wolters F, Oude Elferink RP. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nature Reviews Gastroenterology & Hepatology 2022:1-11.
  9. Di Padova C, Tritapepe R, Rovagnati P, et al. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 1984;6:773-6.
  10. Kuiper EM, van Erpecum KJ, Beuers U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:1334-40.
  11. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006;26:943-8.
  12. easloffice@easloffice.eu EAftSotLEa, Liver EAftSot. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145-172.
  13. Wolfhagen FH, Sternieri E, Hop WC, et al. Oral naltrexone treatment for cholestatic pruritus: a doubleblind, placebo-controlled study. Gastroenterology 1997;113:1264-9.
  14. Terg R, Coronel E, Sordá J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-22.
  15. Mansour-Ghanaei F, Taheri A, Froutan H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006;12:1125-8.
  16. Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007;45:666-74. de Vries E, Bolier R, Goet J, et al. Fibrates for Itch
  17. (FITCH) in Fibrosing Cholangiopathies: A DoubleBlind, Randomized, Placebo-Controlled Trial. Gastroenterology 2021;160:734-743.e6.
  18. Shen N, Pan J, Miao H, et al. Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis. Ann Palliat Med 2021;10:7697-7705.
  19. Peng JK, Hepgul N, Higginson IJ, et al. Symptom prevalence and quality of life of patients with endstage liver disease: A systematic review and metaanalysis. Palliat Med 2019;33:24-36.
  20. Marchesini G, Bianchi G, Amodio P, et al. Factors associated with poor health-related quality of life ofpatients with cirrhosis. Gastroenterology 2001;120:170-178.
  21. Chatrath H, Liangpunsakul S, Ghabril M, et al. Prevalence and morbidity associated with muscle cramps in patients with cirrhosis. Am J Med 2012;125:1019-25.
  22. Vidot H, Cvejic E, Carey S, et al. Randomised clinical trial: oral taurine supplementation versus placebo reduces muscle cramps in patients with chronic liver disease. Aliment Pharmacol Ther 2018;48:704-712.
  23. Houstoun M, Reichman ME, Graham DJ, et al. Use of an active surveillance system by the FDA to observe patterns of quinine sulfate use and adverse hematologic outcomes in CMS Medicare data. Pharmacoepidemiol Drug Saf 2014;23:911-7.
  24. Lee FY, Lee SD, Tsai YT, et al. A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. J Hepatol 1991;12:236-40.
  25. Tapper EB, Salim N, Baki J, et al. Pickle juice intervention for cirrhotic cramps reduction: The PICCLES randomized controlled trial. Official journal of the American College of Gastroenterology| ACG 2022;117:895-901.
  26. Van Thiel DH, Gavaler JS, Sanghvi A. Recovery of sexual function in abstinent alcoholic men. Gastroenterology 1983;84:677-682.
  27. Jagdish RK, Kamaal A, Shasthry SM, et al. Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial. Hepatol Int 2021.
  28. Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. J Hepatol 2016;65:906-913.
  29. Nappi RE, Cucinella L. Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opin Pharmacother 2015;16:875-87.
  30. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New England journal of medicine 1993;329:753-756.
  31. Ghabril M, Jackson M, Gotur R, et al. Most Individuals With Advanced Cirrhosis Have Sleep Disturbances, Which Are Associated With Poor Quality of Life. Clin Gastroenterol Hepatol 2017;15:1271-1278 e6.
  32. Plotogea OM, Ilie M, Bungau S, et al. Comprehensive Overview of Sleep Disorders in Patients with Chronic Liver Disease. Brain Sci 2021;11.
  33. Cordoba J, Cabrera J, Lataif L, et al. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998;27:339-45.
  34. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549-59.
  35. Singh J, Sharma BC, Puri V, et al. Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. Metab Brain Dis 2017;32:595-605.
  36. Sharma MK, Kainth S, Kumar S, et al. Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: A randomized, placebocontrolled trial. Clin Mol Hepatol 2019;25:199-209.
  37. De Silva AP, Niriella MA, Ediriweera DS, et al. Low-dose melatonin for sleep disturbances in earlystage cirrhosis: A randomized, placebo-controlled, cross-over trial. JGH Open 2020;4:749-756.
  38. Spahr L, Coeytaux A, Giostra E, et al. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol 2007;102:744-53.
  39. Tapper EB, Risech-Neyman Y, Sengupta N. Psychoactive Medications Increase the Risk of Falls and Fall-related Injuries in Hospitalized Patients With Cirrhosis. Clin Gastroenterol Hepatol 2015;13:1670-5.
  40. Thomson MJ, Lok AS, Tapper EB. Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis. Hepatology 2020.
  41. Ha A, Saleh ZM, Serper M, et al. Falls are an underappreciated driver of morbidity and mortality in cirrhosis. Clin Liver Dis (Hoboken) 2022;20:146-150.
  42. Holman A, Parikh N, Clauw DJ, et al. Rethinking the management of pain in cirrhosis: toward precision therapy for pain. Hepatology.

Download Tables, Images & References

INTRODUCTION: DISPATCHES FROM THE GUILD CONFERENCE

Dispatches from the GUILD Conference 2023

Read Article

Welcome to the seventh annual Dispatches from GUILD Conference series. The Gastrointestinal Updates-Inflammatory Bowel-Liver Disease (GUILD) Conference is an annual CME conference held in Maui, Hawaii every February (GUILD 2023: February 19-22). We are delighted to offer a hybrid meeting with over 250 health care providers attending live. GUILD again provides cutting edge updates in gastroenterology by world class speakers. Our topics this year include 2 days of IBD updates, a day of hepatology and a day devoted to esophageal disorders. We understand that trainees are our future. Ten Gastroenterology fellows were selected to attend the meeting and receive daily mentoring and networking from our star faculty. GUILD also recognizes the role played by nurse practitioners and physician assistants in the care of IBD and Liver patients and introduced a boot camp in 2019, awarding 10 scholarships to APPs to attend the meeting.

To share our learning with the gastroenterology community at large, we are happy to continue our series beginning with the following article, “The Overlooked Symptoms of Cirrhosis”.

We look forward to providing informative and educational articles covering IBD, Hepatology and special topics in GI in Practical Gastroenterology over the following months. We hope to see you all in person for GUILD 2023 in Maui February 19-22.

For more information on the GUILD Conference, visit: guildconference.com

Download Tables, Images & References

From the Pediatric Literature

From the Pediatric Literature

Read Article

More Diagnostic Use for MMP-7?

The finding of direct hyperbilirubinemia in a neonatal infant is a significant concern as cholestatic disorders, especially biliary atresia, need diagnostic and therapeutic interventions quickly. However, other causes of cholestasis can occur in neonates, especially in those infants receiving total parenteral nutrition (TPN) with resultant cholestasis. Serum matrix metalloproteinase-7 (MMP-7) has shown tremendous promise in helping to diagnose biliary atresia in neonates. Thus, the authors looked at the ability of MMP-7 to differentiate cholestasis caused by biliary atresia versus cholestasis caused by TPN in neonates. 

The authors of the retrospective study evaluated MMP-7 levels in infants less than 6 months of age with conjugated hyperbilirubinemia (defined as a direct hyperbilirubinemia ≥ 1 mg/dL). Infants were defined as having TPN-associated cholestasis if they received TPN in the first 30 days of life, had no other identified cause of cholestasis, had an improvement in cholestasis after stopping TPN, or were found to have normal biliary anatomy upon death and subsequent autopsy. MMP-7 levels were obtained while patients had active cholestasis. A total of 15 patients with TPN-associated cholestasis then were compared to 4 patients with biliary atresia status post hepatoportoenterostomy surgery. Of note, none of the patients with biliary atresia had exposure to TPN.  There was no significant difference in age at which time MMP-7 levels were obtained. The median time of TPN exposure was 50 days (interquartile range: 40-67 days). Infants with TPNassociated cholestasis had a significantly lower gestational age compared to patients with biliary atresia, likely due to their history of prematurity. The authors found that total serum bilirubin levels, direct serum bilirubin, and gamma-glutamyl transferase levels were not significantly different between infants with biliary atresia and infants with TPN-associated cholestasis. However, infants with biliary atresia had a significantly higher MMP-7 level compared to patient with TPN-associated cholestasis (112.3 versus 37.8 ng/mL, P = 0.03). Only one patient with TPN-associated cholestasis had an MMP-7 level in a range similar to patients with biliary atresia. Overall, a serum MMP-7 cutoff level of 52.8 ng/mL in this patient cohort had a sensitivity of 100%, specificity of 93.3% (95% confidence interval 68.1% – 99.8%), positive predictive value of 80% (95% confidence interval 28.4% – 99.5%) and negative predictive value of 100% in identifying cholestasis from biliary atresia versus cholestasis from TPN. No association between time duration of TPN and MMP-7 levels was noted.

Thus, it appears that MMP-7 testing is becoming an important tool in determining the presence of biliary atresia in infants. An elevated MMP-7 level would warrant a quicker intervention (i.e., potential hepatoportoenterostomy) to prevent complications from a delay in a biliary atresia diagnosis. The ability to obtain MMP-7 levels in children’s hospitals and newborn intensive care units is warranted.

Pooja S, Fawaz R, Cowles R. Comparing serum matrix metalloproteinase-7 in parenteral nutrition-associated liver disease and biliary atresia. Journal of Pediatrics 2022; 249: 97-100.

Changes in Outcomes of Pediatric Crohn’s Disease Over Time

Crohn’s disease (CD) in children is increasing in incidence worldwide for reasons that are not clear. Immunosuppressant (azathioprine, 6-mercaptopurie, methotrexate) and anti-tumor necrosis factor alpha (anti-TNF-α) medications (infliximab, adalimumab, etc.) are being used much more frequently in pediatric patients with CD, and the authors evaluated changes in outcomes in pediatric patients with CD over time via a population study using a pediatric cohort of patients with CD. Patients for this study came from EPIMAD, which is a longitudinal and prospective study of patients with inflammatory bowel disease (IBD) in northern France. All patients diagnosed with CD between 1988 and 2011 that were younger than 17 years of age were evaluated in this database to see if immunosuppressant and anti-TNF-α therapy reduced pediatric CD complications. Patients were evaluated from 1988 to 1993 (the period before immunosuppressant use), 1994 to 2000 (the period before anti-TNF-α use), and 2001 to 2011 (the period when anti-TNF-α therapy was used). Outcomes, including CD disease behavior, intestinal resection, and hospitalization due to CD flares were compared during these three time periods. 

A total of 1007 pediatric patients with CD were evaluated using the EPIMAD registry. Females comprised 44.8% of the study with the median age at diagnosis being 14.5 years (IQR (interquartile range), 12.0–16.1 years) and the median duration of patient follow-up being 8.8 years (IQR, 4.6–14.2 years). Ileocolonic disease was present in 54.9% of patients. There were 167 pediatric patients (16.7%) enrolled during the time period before immunosuppressant use, 260 patients (25.8%) enrolled during the time period before anti-TNF-α use, and 580 patients (57.5%) enrolled during the time period when anti-TNF-α therapy was used. The authors noted that a 5-year cumulative exposure rate to exclusive enteral nutrition increased significantly throughout the three time periods while the 5-year cumulative exposure rate to any type of corticosteroid did not significantly change. The 5-year cumulative exposure rate to immunosuppressant therapy and anti-TNF-α significantly increased throughout the study while age in years at first exposure to immunosuppressant therapy and anti-TNF-α decreased significantly throughout the study. The exposure rate to a combination of these two types of CD therapies increased significantly throughout the study. Progression to CD-associated stricturing complications decreased significantly over time while progression to CD-associated penetrating disease did not significantly change over time. The authors also noted that the cumulative 5-year intestinal resection rate decreased significantly throughout the study while the 5-year cumulative hospitalization rate for CD-related flares did not significantly change.

This study appears to show that new therapies for pediatric CD may be affecting disease outcomes with the encouraging effects of less stricturing disease and less requirement for intestinal resection. Since children with CD appear to have a higher rate of identifiable genetic causes for immune dysfunction in the setting of CD compared to adults, the long-term use of immunosuppressant therapy and anti-TNF-α in this scenario is still unknown. However, the results of this study suggest that the introduction of new therapies for CD in children appear to be clinically effective.

Ley D, Leroyer A, Dupont C, Sarter H, Bertrand V, Spyckerelle C, Guillon N, Wils P, Savoye G, Turck D, Gower-Rousseau C, Fumery M, on behalf of the Epimad Group. New therapeutic strategies have changed the natural history of pediatric Crohn’s disease: a two-decade population-based study. Clinical Gastroenterology and Hepatology 2022; 20: 2588-2597.

Download Tables, Images & References

FRONTIERS IN ENDOSCOPY, SERIES #85

Endohepatology: A New Realm for Endoscopic Ultrasound

Read Article

INTRODUCTION

With advancements in endoscopic ultrasound (EUS) and its expanding role in management of liver disease, has come a new field that has been termed Endohepatology. Traditionally, liver disease and its comorbidities have been inspected by interventional radiology using percutaneous methods. With the emergence of the field of endohepatology, EUS-guided alternatives to the traditional percutaneous routes for procedures such as liver biopsy (LB), portal pressure measurement, and treatment of gastric varices have been developed and have entered practice. This manuscript will review the current state of endohepatology, discuss endoscopic diagnostic and therapeutic tools and techniques, and analyze the data comparing traditional methods to new endoscopic methods of diagnosis and treatment of patients with liver disease.

EUS Guided Liver Biopsy

EUS-LB is a unique approach to liver biopsy because of its ability to obtain samples from the liver without traversing the skin. EUS-LB is performed using a standard linear echoendoscope which provides high-quality, real-time views of the liver and surrounding solid and vascular structures. This allows for precise needle placement in both normal liver parenchyma and, on some occasions, liver lesions. Doppler ultrasound also prevents injury to interposed vascular structures.1

EUS-LB is typically performed using either a 19-gauge or a 22-gauge needle, although most practitioners utilize a 19-gauge needle as it provides a much larger and less fragmented sample.2 (Figure 1 and Figure 2) A variety of approaches and techniques are available, but many centers utilize the technique proposed by Diehl et al. using heparinized needles with wet suction.3 Typically, studies of EUS-LB specimens compare efficacy of needle sizes and models by assessing the tissue obtained via their use. Studies compare length of the longest piece (LLP), intact specimen length (ISL), total specimen length (TSL), the number of complete portal triads (CPTs), tissue adequacy, and adverse events. A recent study comparing a 19G fine-needle aspiration device (FNA) to 22G fine-needle biopsy (FNB) showed a tissue adequacy, measured by number of portal structures in the sample, of 88% in 19G FNA vs. 68% in 22G FNB.2 It was found that since the 22G FNB produced thinner samples than the 19G FNA, they were prone to fragmentation during tissue processing.

There are several different techniques for EUSLB. For retrieving the sample, there is a “slow pull” technique, as well as a “wet suction” technique, and they are often combined in practice. The “slow pull” technique uses minimal suction via the gradual removal of the stylet during the needle actuations and is useful in collecting samples with less blood and more tissue. The “wet suction” technique involves flushing the needle with saline or, more commonly, heparin with the addition of suction. It was found that priming the needle with an anticoagulant had no adverse effects on the sample and helped to resolve the issue of blood collection and reduced sample fragmentation.3,4

Other traditional methods of liver biopsy include the Percutaneous route (PC) and the Transjugular route (TJ). The PC route uses spring-loaded 18G, 19G, or 20G needles, while the TJ route uses either an 18G or 19G needle.5 One of the primary concerns with EUS-LB was that the limitations of needle size to 19G would produce smaller and lower quality samples than the other two routes. However, when EUS-LB was compared to PC and TJ routes, it was found that EUS-LB produced more tissue with a greater TSL. The number of CPTs were greater in the EUS-LB samples than PC, but equivalent to TJ.5 Once rarely performed, EUS-LB is now entering widespread usage in the United States. In one study, diagnostic accuracy was found to be similar between EUS-LB and PC-LB.6 This study found a diagnostic adequacy rate of 100% in PC-LB and 94.4% in EUS-LB (p = 0.74); the study also showed a diagnostic accuracy rate of 100% in PC-LB and 88.8% in EUS-LB (p = 0.82). Another study comparing PC-LB and EUS-LB showed a sensitivity, specificity, and accuracy of 95%, 100%, and 96% in the PC group and 100%, 100%, and 100% in the EUS group, respectively, showing no significant difference.7 Adverse events associated with EUS, PC, and TJ liver biopsy include pain, intraperitoneal and subcapsular hemorrhage, bile peritonitis, inadvertent sampling of other organs, pneumothorax, and infection.5 There has been conflicting evidence with regards to adverse event rates between EUS-LB and PC-LB.8,9

One study has shown adverse event rates of 17% in patients undergoing PC-LB versus 2% among patients undergoing EUS-LB (p< 0.01).8 However, another study showed that adverse event rates in both PC-LB and EUS-LB were 0%, although this may be an outlier in both respects.9 Studies done separately from one another have also shown that liver biopsy via EUS, PC, and TJ routes all have similar adverse event rates. A meta-analysis performed to assess the efficacy and safety of EUS-LB found across 8 studies a pooled adverse event rate of 2.3%.10 A study on PC-LB showed adverse event rates between 0.09% and 3.1%, and another study on TJ-LB had adverse event rates between 0.56% and 6.5%.11,12 There are several variations in needle models, size, and tip design. The options for EUS-LB needle tip design include: Franseen-Type, a

needle with 3 cutting tips; Fork-Tip-Type, a needle with 2 parallel cutting tips; Menghini-Type, a needle with a beveled end cutting edge; and the ProCore, a needle with an end cutting beveled edge and a core trap near the tip.13 A study comparing these models found that all samples obtained with 19G and 20G needles, regardless of model, had statistically similar mean numbers of CPTs. It also found that yields of the 19G and 20G needles were statistically superior to the 22G SharkCore ForkTip-Type needle, further suggesting the inadequacy of 22G needles for EUS-LB. This study found statistically significant evidence that the Acquire Franseen-Type 19G needle produced longer tissue fragments than all the other needle types tested, except for the EZ Shot 3 Plus Menghini-Type 19G needle.13 Three studies have compared the Franseen-Type needle design to the Fork-Tip-Type. Across these studies, Franseen-Type needles had a statistically significant higher number of CPTs than the ForkTip-Type needle (14.4 vs. 9.5 with p = 0.043; 9.59 vs. 7.07 with a p < 0.001; 24.0 vs. 19.5 with a p < 0.01).14,15,16 When comparing specimen length and histological adequacy, there are conflicting findings. Of these 3 studies, 2 found that the Franseen-Type had statistically significant longer specimen length (15.81mm vs. 13.86mm with p = 0.004; 31mm vs. 27mm with p = 0.01).15,16 The remaining study found no significant difference in specimen length (44.9mm vs. 34.6mm with p = 0.097).14 Two of these studies also compared histological adequacy of the tissue samples collected. One study showed no statistically significant difference between the two needles with adequacy at 100% in the Franseen-Type and 95.5% in the Fork-Tip-Type (p = 0.312).14 The other study, however, showed a histologic adequacy of 97.2% in the FranseenType and 79.4% in the Fork-Tip-Type (p = 0.001).15

EUS Guided Portal Pressure Measurement

The portal pressure gradient (PPG) is a measurement that is useful in assessing the degree of portal hypertension (PH) and the severity of cirrhosis. Currently, the standard for PH assessment is the use of an indirect PC method that measures the hepatic venous pressure gradient (HVPG) via a transjugular approach.17

EUS-guided portal vein pressure (PVP) measurement is performed using a linear echoendoscope, a 25G needle, and a compact, one-time-use pressure manometer with noncompressible tubing.18 To calculate the PPG, pressure measurements need to be made in both the hepatic vein (HV) and portal vein (PV), and then the HV pressure is subtracted from the PV pressure. Access to the HV is possible by first identifying the inferior vena cava (IVC), with the echoendoscope located at the gastroesophageal junction. Any of the three hepatic vein branches can be used for measurement after identification.18 (Figure 3) The PV pressure measurement is made in the intrahepatic PV near the PV bifurcation. (Figure 4) Manometry of the PV is performed usually with a transgastric approach. However, an alternative transduodenal, transhepatic approach can be utilized as well.18

Studies performed that compared the EUS-PPG measurement to indirect TJ HVPG measurement have found no statistically significant difference in accuracy.19 In one study, each participant had their PVP measured first with the EUS-PPG method, followed by the indirect TJ method. When PVP values from each method were compared in a linear relationship, a Pearson’s correlation coefficient of 0.923 and 95% confidence interval (CI) of 0.6369 to 0.9821; and an R2 value of 0.852; was found. This shows remarkable consistency between the two methods. Similarly, when comparing the mean PVP findings between the two methods, they also found no significant difference (p = 0.231).19 Another comparison study had similar results. The study found that the Pearson’s correlation coefficient was 0.999 for all vessels, 0.985 for all veins, 0.988 for PV and wedged hepatic venous pressure, and 0.986 for free HV pressure.20 It should be noted that the PVP obtained by interventional radiologists is indirect, as it is a wedged pressure obtained in the HV, but during EUS-PPG the PVP is, in fact, measured directly.

It was also found that EUS-PPG and indirect TJ HVPG do not have a statistically significant difference in procedure time. In one study, the average procedure time for EUS-PPG was 38.33 minutes; for indirect TJ HVPG it was 37.22 minutes (p = 0.862).19 EUS-PPG has shown specific benefit in the measurement of PVP in patients with BuddChiari syndrome (hepatic vein occlusion subtype). In one study, 2 of the participants were diagnosed with Budd-Chiari syndrome. For these participants, it was not possible to obtain PVP using the indirect TJ method, however, EUS-PPG was still measured successfully.19 Adverse events with either method include bleeding, infection, thrombosis, or perforation. Across 5 studies, no adverse events were recorded with EUS-PPG, nor the indirect TJ method.19,20,21,22,23

EUS Guided Gastric Variceal Coiling and Gluing

There are three different classification systems commonly used for gastric varices (GV): Sarin’s classification, Hashizome’s classification, and Arakawa’s classification. Sarin’s classification is

the most commonly used method.24 In this system, GVs are categorized into 4 types based on location and relationship with esophageal varices (EV). Types include gastroesophageal varices (GOV) Type 1 and 2, and isolated gastric varices (IGV) Type 1 and 2. GOV type 1 is described as EVs that extend down the lesser curvature of the stomach, whereas GOV type 2 is described as EVs that extend down the greater curvature of the stomach. Type 1 IGV are GVs that exist exclusively in the fundus of the stomach, whereas IGV type 2 is defined as ectopic varices that occur in other parts of the stomach or duodenum.24,25

In one study, GVs were present in 20% of patients with PH at initial evaluation. The incidence of bleeding was greatest in IGV type 1 at 78%. When compared with isolated EVs, GVs bled in significantly fewer patients (64% vs. 25%). Although GVs had a lower bleeding risk than EVs, when they did bleed it was more severe. In this study, a bleeding GV was found to have a high mortality rate of 45%.25

Treatment options for GVs include endoscopic sclerotherapy, endoscopic variceal ligation (EVL), endoscopic variceal obturation with tissue adhesive such as cyanoacrylate glue (CYA), fibrin glue, or thrombin, EUS-guided coil deployment, balloon tamponade, a transjugular intrahepatic portosystemic shunt (TIPS) procedure, or balloonoccluded retrograde transvenous obliteration (BRTO).26,27,28 TIPS is the most commonly performed procedure for GVs secondary to portal hypertension. The preferred initial endoscopic treatment option is cyanoacrylate glue or fibrin injection and/or coil deployment.27,28 (Figure 5) Approaches in practice remain nonstandardized. Glue injection can be performed with either direct endoscopy or under the guidance of EUS. A recent comparative study showed that EUS-guided glue injection required less glue and had decreased rebleeding rates, with no significant difference in adverse events, when compared with direct endoscopic glue injection.29 

CYA glue has multiple monomers available for use, including N-butyl-2-cyanoacrylate (NB2CYA) and 2-octyl-cyanoacrylate (2O-CYA). What makes each monomer unique is the size of their alkyl group; NB2-CYA has a 4-carbon alkyl group, whereas 2O-CYA has an 8-carbon alkyl group.26 The longer the alkyl group, the longer the polymerization time of the glue will be. The polymerization time for NB2-CYA is so short it can cause premature solidification of glue inside a delivery needle or within a varix, risking entrapment of the needle. To prevent premature solidification of the glue, NB2-CYA is diluted with Lipiodol. Since 2O-CYA has a longer polymerization time, dilution is not required.26 As an alternative to CYA glue injection, one could also use absorbable gelatin sponge (AGS) in the treatment of GVs. AGS is a purified collagen that forms a plug by absorbing 45 times its volume in blood.30

EUS-guided coil deployment utilizes stainless steel micro-coils that reduce the rate of blood flow and promote thrombosis of the varix.28 When coil and glue monotherapy have been compared, it has been shown that they share similar hemostasis rates and have no significant difference in the number of sessions required for obliteration (p = 0.29).29 Coils do however, have statistically significant fewer adverse events when compared to glue injection (p < 0.1).29

It has been found that when glue injection and coil deployment are combined it is more efficient than either alone, with decreased recurrence rates, volumes of glue, and numbers of coils required.31,32 One study also showed that combination therapy had statistically significant higher rates of technical and clinical success than either alone (p < 0.001).32 Potential adverse events from the use of CYA glue, thrombin injection, or coil deployment include pulmonary or systemic embolization, visceral fistulization, ulceration and bleeding at the injection site, peritonitis, needle impaction, traumatic withdrawal due to glue adherence to the needle, coil extrusion, and death.26,32,33 One study compared glue and coil monotherapy and found that adverse event rates were statistically significantly higher with CYA glue injection (58%) than coil (9%) deployment (p < 0.01).26 Another study that compared glue and coil combination therapy with each of these agents as monotherapy found that combination therapy had statistically significant fewer adverse events than glue monotherapy (10% vs. 21%; p < 0.001). This same study also found that combination therapy did not have a statistically significant difference in adverse event rates when compared with coil monotherapy (10% vs. 3%; p = 0.057).32

Conclusion

Endohepatology is an emerging field with novel, minimally invasive diagnostic and therapeutic options for patients with liver disease. EUS guided liver biopsy, portal pressure measurement, and gastric variceal treatment are commercially available and remain targets of active investigation as promising alternatives to the current standard of care. Future studies will likely further refine the role of these interventions.

References

  1. Saraireh HA, Bilal M, Singh S. Role of endoscopic ultrasound in liver disease: Where do we stand in 2017? World J Hepatol. 2017 Aug 28;9(24):1013-1021. doi: 10.4254/wjh.v9.i24.1013. PMID: 28932347; PMCID: PMC5583533.
  2. Mok SRS, Diehl DL, Johal AS, Khara HS, Confer BD, Mudireddy PR, Kovach AH, Diehl MM, Kirchner HL, Chen ZE. Endoscopic ultrasound-guided biopsy in chronic liver disease: a randomized comparison of 19-G FNA and 22-G FNB needles. Endosc Int Open. 2019 Jan;7(1):E62-E71. doi: 10.1055/a-0655-7462. Epub 2019 Jan 4. PMID: 30648141; PMCID: PMC6327728.
  3. Diehl DL, Mok SRS, Khara HS, Johal AS, Kirchner HL, Lin F. Heparin priming of EUS-FNA needles does not adversely affect tissue cytology or immunohistochemical staining. Endosc Int Open. 2018 Mar;6(3):E356-E362. doi: 10.1055/s-0043-121880. Epub 2018 Mar 7. PMID: 29527558; PMCID: PMC5842078.
  4. Mok SRS, Diehl DL, Johal AS, Khara HS, Confer BD, Mudireddy PR, Kirchner HL, Chen ZE. A prospective pilot comparison of wet and dry heparinized suction for EUSguided liver biopsy (with videos). Gastrointest Endosc. 2018 Dec;88(6):919-925. doi: 10.1016/j.gie.2018.07.036. Epub 2018 Aug 16. PMID: 30120956.
  5. Pineda JJ, Diehl DL, Miao CL, Johal AS, Khara HS, Bhanushali A, Chen EZ. EUS-guided liver biopsy provides diagnostic samples comparable with those via the percutaneous or transjugular route. Gastrointest Endosc. 2016 Feb;83(2):360-5. doi: 10.1016/j.gie.2015.08.025. Epub 2015 Aug 22. PMID: 26301407.
  6. Facciorusso A, Ramai D, Conti Bellocchi MC, Bernardoni L, Manfrin E, Muscatiello N, Crinò SF. Diagnostic Yield of Endoscopic Ultrasound-Guided Liver Biopsy in Comparison to Percutaneous Liver Biopsy: A Two-Center Experience. Cancers (Basel). 2021 Jun 19;13(12):3062. doi: 10.3390/cancers13123062. PMID: 34205389; PMCID: PMC8235406.
  7. Takano Y, Noda J, Yamawaki M, Azami T, Kobayashi T, Niiya F, Maruoka N, Norose T, Ohike N, Wakabayashi T, Matsuo K, Tanaka K, Nagahama M. Comparative Study of an Ultrasound-guided Percutaneous Biopsy and Endoscopic Ultrasound-guided Fine-needle Aspiration for Liver Tumors. Intern Med. 2021;60(11):1657-1664. doi: 10.2169/internalmedicine.6183-20. Epub 2021 Jun 1. PMID: 34078770; PMCID: PMC8222129.
  8. Takano Y, Noda J, Yamawaki M, Azami T, Kobayashi T, Niiya F, Maruoka N, Norose T, Ohike N, Wakabayashi T, Matsuo K, Tanaka K, Nagahama M. Comparative Study of an Ultrasound-guided Percutaneous Biopsy and Endoscopic Ultrasound-guided Fine-needle Aspiration for Liver Tumors. Intern Med. 2021;60(11):1657-1664.doi: 10.2169/internalmedicine.6183-20. Epub 2021 Jun 1. PMID: 34078770; PMCID: PMC8222129.
  9. Ali AH, Panchal S, Rao DS, Gan Y, Al-Juboori A, Samiullah S, Ibdah JA, Hammoud GM. The efficacy and safety of endoscopic ultrasound-guided liver biopsy versus percutaneous liver biopsy in patients with chronic liver disease: a retrospective single-center study. J Ultrasound. 2020 Jun;23(2):157-167. doi: 10.1007/s40477-02000436-z. Epub 2020 Mar 5. PMID: 32141043; PMCID: PMC7242589.
  10. Mohan BP, Shakhatreh M, Garg R, Ponnada S, Adler DG. Efficacy and safety of EUS-guided liver biopsy: a systematic review and meta-analysis. Gastrointest Endosc. 2019 Feb;89(2):238-246.e3. doi: 10.1016/j.gie.2018.10.018. Epub 2018 Oct 31. PMID: 30389469.
  11. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009 Mar;49(3):101744. doi: 10.1002/hep.22742. PMID: 19243014.
  12. Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, Patch D, Burroughs AK. Transjugular liver biopsy–indications, adequacy, quality of specimens, and complications–a systematic review. J Hepatol. 2007 Aug;47(2):284-94. doi: 10.1016/j. jhep.2007.05.001. Epub 2007 May 24. PMID: 17561303.
  13. Eskandari A, Koo P, Bang H, Gui D, Urayama S. Comparison of Endoscopic Ultrasound Biopsy Needles for Endoscopic Ultrasound-Guided Liver Biopsy. Clin Endosc. 2019 Jul;52(4):347-352. doi: 10.5946/ce.2019.005. Epub 2019 Jul 10. PMID: 31288504; PMCID: PMC6680021.
  14. Hashimoto R, Lee DP, Samarasena JB, Chandan VS, Guo W, Lee JG, Chang KJ. Comparison of Two Specialized Histology Needles for Endoscopic Ultrasound (EUS)Guided Liver Biopsy: A Pilot Study. Dig Dis Sci. 2021 May;66(5):1700-1706. doi: 10.1007/s10620-020-063913. Epub 2020 Jun 17. PMID: 32556821.
  15. Aggarwal SN, Magdaleno T, Klocksieben F, MacFarlan JE, Goonewardene S, Zator Z, Shah S, Shah HN. A prospective, head-to-head comparison of 2 EUS-guided liver biopsy needles in vivo. Gastrointest Endosc. 2021 May;93(5):1133-1138. doi: 10.1016/j.gie.2020.09.050. Epub 2020 Oct 9. PMID: 33045222.
  16. Nieto J, Dawod E, Deshmukh A, Penn E, Adler D, Saab S. EUS-guided fine-needle core liver biopsy with a modified one-pass, one-actuation wet suction technique comparing two types of EUS core needles. Endosc Int Open. 2020 Jul;8(7):E938-E943. doi: 10.1055/a-11651767. Epub 2020 Jun 16. PMID: 32617398; PMCID: PMC7297611.
  17. Samarasena JB, Yu AR, Chang KJ. EUS-guided portal pressure measurement (with videos). Endosc Ultrasound. 2018 Jul-Aug;7(4):257-262. doi: 10.4103/eus.eus_35_18. PMID: 30117489; PMCID: PMC6106144.
  18. Huang JY, Samarasena JB, Tsujino T, Lee J, Hu KQ, McLaren CE, Chen WP, Chang KJ. EUS-guided portal pressure gradient measurement with a simple novel device: a human pilot study. Gastrointest Endosc. 2017 May;85(5):996-1001. doi: 10.1016/j.gie.2016.09.026. Epub 2016 Sep 29. PMID: 27693644; PMCID: PMC5611853.
  19. Zhang W, Peng C, Zhang S, Huang S, Shen S, Xu G, Zhang F, Xiao J, Zhang M, Zhuge Y, Wang L, Zou X, Lv Y. EUS-guided portal pressure gradient measurement in patients with acute or subacute portal hypertension. Gastrointest Endosc. 2021 Mar;93(3):565-572. doi: 10.1016/j.gie.2020.06.065. Epub 2020 Jun 29. PMID: 32615178.
  20. Huang JY, Samarasena JB, Tsujino T, Chang KJ. EUSguided portal pressure gradient measurement with a novel 25-gauge needle device versus standard transjugular approach: a comparison animal study. Gastrointest Endosc. 2016 Aug;84(2):358-62. doi: 10.1016/j.gie.2016.02.032.Epub 2016 Mar 3. PMID: 26945557.
  21. Samarasena JB, Chang KJ. Endoscopic UltrasoundGuided Portal Pressure Measurement and Interventions. Clin Endosc. 2018 May;51(3):222-228. doi: 10.5946/ ce.2018.079. Epub 2018 May 31. PMID: 29874904; PMCID: PMC5997067.
  22. Shah SL, Dawod Q, Kumar S, Fortune B, Sharaiha RZ. “One stop” liver-focused endoscopy: EUS-guided portal pressure gradient measurement technique. VideoGIE. 2020 Sep 25;5(12):658-659. doi: 10.1016/j.vgie.2020.08.006. PMID: 33319134; PMCID: PMC7732719.
  23. Samarasena JB, Huang JY, Tsujino T, Thieu D, Yu A, Hu KQ, Lee J, Chang KJ. EUS-guided portal pressure gradient measurement with a simple novel device: a human pilot study. VideoGIE. 2018 Oct 25;3(11):361-363. doi: 10.1016/j.vgie.2018.07.013. PMID: 30402586; PMCID: PMC6205538.
  24. Wani ZA, Bhat RA, Bhadoria AS, Maiwall R, Choudhury A. Gastric varices: Classification, endoscopic and ultrasonographic management. J Res Med Sci. 2015 Dec;20(12):1200-7. doi: 10.4103/1735-1995.172990. PMID: 26958057; PMCID: PMC4766829.
  25. Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology. 1992 Dec;16(6):13439. doi: 10.1002/hep.1840160607. PMID: 1446890.
  26. Weilert F, Binmoeller KF. Endoscopic management of gastric variceal bleeding. Gastroenterol Clin North Am. 2014 Dec;43(4):807-18. doi: 10.1016/j.gtc.2014.08.010. Epub 2014 Sep 12. PMID: 25440927.
  27. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007 Sep;46(3):92238. doi: 10.1002/hep.21907. Erratum in: Hepatology. 2007 Dec;46(6):2052. PMID: 17879356.
  28. Rodge GA, Goenka U, Goenka MK. Management of Refractory Variceal Bleed in Cirrhosis. J Clin Exp Hepatol. 2022 Mar-Apr;12(2):595-602. doi: 10.1016/j. jceh.2021.08.030. Epub 2021 Sep 4. PMID: 35535060; PMCID: PMC9077219.
  29. Romero-Castro R, Ellrichmann M, Ortiz-Moyano C, Subtil-Inigo JC, Junquera-Florez F, Gornals JB, Repiso-Ortega A, Vila-Costas J, Marcos-Sanchez F, Muñoz-Navas M, Romero-Gomez M, Brullet-Benedi E, Romero-Vazquez J, Caunedo-Alvarez A, PellicerBautista F, Herrerias-Gutierrez JM, Fritscher-Ravens A. EUS-guided coil versus cyanoacrylate therapy for the treatment of gastric varices: a multicenter study (with videos). Gastrointest Endosc. 2013 Nov;78(5):711-21. doi: 10.1016/j.gie.2013.05.009. Epub 2013 Jul 25. PMID: 23891417.
  30. Bazarbashi AN, Wang TJ, Thompson CC, Ryou M. Endoscopic ultrasound-guided treatment of gastric varices with coil embolization and absorbable hemostatic gelatin sponge: a novel alternative to cyanoacrylate. Endosc Int Open. 2020 Feb;8(2):E221-E227. doi: 10.1055/a-10276708. Epub 2020 Jan 28. PMID: 32010757; PMCID: PMC6986946.
  31. Bhat YM, Weilert F, Fredrick RT, Kane SD, Shah JN, Hamerski CM, Binmoeller KF. EUS-guided treatment of gastric fundal varices with combined injection of coils and cyanoacrylate glue: a large U.S. experience over 6 years (with video). Gastrointest Endosc. 2016 Jun;83(6):116472. doi: 10.1016/j.gie.2015.09.040. Epub 2015 Oct 9. PMID: 26452992.
  32. McCarty TR, Bazarbashi AN, Hathorn KE, Thompson CC, Ryou M. Combination therapy versus monotherapy for EUS-guided management of gastric varices: A systematic review and meta-analysis. Endosc Ultrasound. 2020 Jan-Feb;9(1):6-15. doi: 10.4103/eus.eus_37_19. PMID: 31417066; PMCID: PMC7038733.
  33. Oleas R, Robles-Medranda C. Endoscopic Treatment of Gastric and Ectopic Varices. Clin Liver Dis. 2022 Feb;26(1):39-50. doi: 10.1016/j.cld.2021.08.004. Epub 2021 Oct 27. PMID: 34802662.

Download Tables, Images & References

FUNDAMENTALS OF ERCP, SERIES #3

Endoscopic Sphincterotomy

Read Article

INTRODUCTION

After      the       first     description      of         diagnostic       ERCP  by McCune et al. in 1968,1 it was not long before biliary sphincterotomy was developed. Initial description of the technique of biliary sphincterotomy came simultaneously in 1974 from Kawai in Japan,2 and Classen in Germany.3 The general construction of the sphincterotome was a single lumen catheter with an electrocautery wire that could be “bowed” when put under tension via traction.

The development of multilumen catheters soon followed, which allowed for separate lumens for the cutting wire and either contrast injection or guidewire placement (Figure 1).  Further refinements     of the bowing sphincterotome included triple lumen catheters (which could allow contrast injection with a guidewire in the catheter at the same time),  variations in cutting wire length  and sphincterotome tip geometry, and pre-curved catheters. Specialty variations of sphincterotomes have included rotatable design, bipolar cautery, ultra-tapered tips, and the reverse-orientation “Billroth II sphincterotome”. The general structure of the endoscopic sphincterotome has been remarkably stable for the past 20 years, and it is truly impressive that this rather straightforward and inexpensive device remains the workhorse of the advanced endoscopist’s toolbox when performing ERCP.

In the past, the term “papillotomy” was often used, although is rarely used anymore in favor of the term “sphincterotomy.”

Use of Abbreviations in this Article

For the sake of brevity and clarity, the following abbreviations will be used to describe the different variations of sphincterotomy:

ES  endoscopic sphincterotomy

bES  biliary sphincterotomy

mbES  minimal biliary sphincterotomy

pES  pancreatic sphincterotomy

mpES  minor papilla sphincterotomy

NKS  needle knife sphincterotomy

NKF needle knife fistulotomy

Indications for Endoscopic Biliary Sphincterotomy (bES)

The decision to perform bES is dependent on several factors including indication for the procedure, concomitant use of anti-coagulant or anti-platelet medications,  the presence or absence of         significant coagulopathy, and anatomical considerations such bile duct, and anatomical considerations. A longer sphincterotomy may be needed for removal of large biliary stones as opposed to a shorter length for placing a stent to palliate a biliary stricture or to facilitate device access into the bile duct.7

The most common indication for bES is for the management of choledocholithiasis.8 When anatomically feasible, a longer sphincterotomy is performed for management of larger common bile duct stones.9 However, bES in conjunction with papillary balloon dilation can obviate the need for a long sphincterotomy for removal of large bile duct stones.10 Management of iatrogenic or traumatic bile leaks is a common indication for ERCP.11 Performing bES decreases the trans-papillary pressure gradient and facilitates preferential drainage of bile into the duodenum.11,12 Functional biliary sphincter disorder, formerly referred to as sphincter of Oddi dysfunction (SOD), is another  indication for bES, although endoscopic management strategies for this set of as altered surgical anatomy or an intra-diverticular papilla.4,5,6 The length of the sphincterotomy is tailored for the procedural indication, size of the conditions remain controversial, and many centers have abandoned the entire concept of SOD.13,14 According to the Rome IV criteria, patients with a dilated common bile duct and elevated liver  function          tests     (formerly        SOD    type     1)         should            undergo ERCP with bES. Other indications for bES are papillary stenosis, a type 3 choledochal cyst          (choledochocele),       sump   syndrome,       biliary            parasitic infections, and to facilitate access for biliary interventions, most importantly biliary stent placement.15

Contraindications for Endoscopic Biliary Sphincterotomy

An uncooperative patient is a contraindication for ERCP and bES. bES is classified as a          procedure with an elevated risk of bleeding according to the American Society for Gastrointestinal Endoscopy (ASGE) guidelines.16 However, minimal EBS (mbES) with papillary dilation  has been shown  to be safe in the setting of anti-platelet or anticoagulant use, although the indications for mbES are relatively uncommon.17 Although hepatic cirrhosis has been associated with higher rates of sphincterotomy bleeding,26 this is not strictly considered an contraindication for bES. Altered patient anatomy such as a duodenal diverticulum or Billroth II gastrojejunostomy can increase the difficulty    of            bES,    however          the       procedure        can      be        safely performed in this setting.7,15

Technique of Biliary Sphincterotomy (bES) Device selection

For cannulation of native papillae, most endoscopists favor the use of a bowing sphincterotome over a straight biliary catheter because the ability to bow the tip of the device can help achieve the proper angle for cannulation, and bES can be performed without the need for device exchange. Earlier sphincterotome designs had cutting wire lengths from 15mm to 40mm, and “nose length,” also referred to as “tip length,” up to 3-4cm. Most current sphincterotomes have short tips. Current models of bowing sphincterotomes have cutting wire lengths of 20, 25, or 30mm, and selection between these lengths is mainly user preference. Shorter cutting wires can be bowed with less of the tip of the device extended beyond the working channel, while longer cutting wires generate a more severe deformation of the sphincterotome during the act of bowing. Sphincterotomes can be “long wire” or “short wire” platforms, with the latter allowing physician-controlled guidewire manipulation for cannulation which has been found to be advantageous.18

Needle       knife    sphincterotomy           (NKS) was      first     described        in            1986    by        Huibrigtse       et         al.19  Historically, this was a rarely used technique, but it has gained more importance and adoption over the last several years. A needle-knife sphincterotome is a double or triple lumen catheter with a thin electrocautery needle at the tip that can be extended and withdrawn. It is mainly used in cases of difficult biliary cannulation after standard attempts at achieving duct access have failed.

Billroth-II anatomy is less frequently encountered anymore as surgical management of peptic ulcer disease has declined since introduction of potent antisecretory medications. Still, patients with Billroth-II anatomy are still encountered and a knowledge and understanding of how to perform biliary sphincterotomy in these patients is important. A dedicated Billroth-II sphincterotome is still available from Cook Medical (Bloomington,IN) but most modern endoscopists favor the use of a rotatable sphincterotome (Autotome, Boston Scientific, Marlborough, MA). Another effective technique in Billroth-II anatomy is to perform NKS over a previously placed biliary stent.

Landmarks for Biliary Sphincterotomy (bES) What direction?

The direction of cut of the biliary sphincterotomy is along the long axis of the intraduodenal mound. This long axis is generally called the “12 o’clock direction”, invoking the directions of a clock      face     (Figure 2A       and      2B).     It          is acceptable       for the sphincterotomy incision to be carried out anywhere from an 11 o’clock to a 1 o’clock direction, although most avoid cutting in the 1 o’clock position if possible. Sphincterotomy outside of that “wedge” may carry an increased risk of pancreatitis, perforation, and/or bleeding.

How long?

Above  the orifice of the ampulla of Vater,  the distal common bile duct (CBD) is intraduodenal. This intraduodenal portion creates a “mound” of varying size in different patients. Sometimes the mound is quite prominent, or even bulging (Figure 3A).        This     can      occur   when   a stone   is         impacted at the papillary orifice or when there is diffuse dilation of the entire   common bile duct     (CBD). In some cases, an ampullary tumor can show a large ampullary bulge   (Figure 3B).     A         chledochocele (type    III        choledochal    cyst)    is another cause   for       a          bulging            ampulla           (Figure 3D).     In many   cases,  the mound is small. As a general rule, the extent of the biliary sphincterotomy can be taken to the entire length of the mound. Caution should be taken with very small papillae, as the mound is small and the length of cut necessarily needs to be shorter. Caution also should be exercised with sphincterotomy of ampullae that are on the edge     of         or         in         a          diverticulum   (Figure 4A       and 4B)      since the risk of perforation and bleeding is felt to be higher.20 In cases such as these, consideration should be given for limited sphincterotomy or even mbES, followed by balloon sphincteroplasty, but most patients with a periampullary diverticulum can undergo a complete biliary sphincterotomy.17

Cautery settings

For most of the early years of bES, “blended” (cutting         and      coagulation) current was      used     through           the sphincterotome wire to create the cut. Care had to be taken to avoid cutting too fast (the dreaded “zipper           cut”),   which could   introduce         complications of bleeding or perforation. The introduction of a pulse cut mode in 1997 (EndoCut, ERBE, Tübingen, Germany)      was      almost revolutionary  for       the       field,   as “pulse cut” energy gradually took over as the preferred energy mode for biliary sphincterotomy. Modern endoscopic generators allow cutting and coagulating current to be used in an alternating manner during endoscopic sphincterotomy.

Troubleshooting

A common challenge is for the cutting wire to not be in the ideal 12 o’clock position prior to initiating the sphincterotomy. Generally, it is acceptable for the wire to be in the range of 11 o’clock to 1 o’clock, and to cut with the “side of the wire” to complete the sphincterotomy. However, if the orientation is still not adequate, sometimes the distal 3cm of the sphincterotome needs to be “groomed” to achieve the ideal direction. In the days before all sphincterotomes were “pre-curved” at the factory, endoscopists routinely groomed the tip of the sphincterotome.21 The other approach to improving sphincterotome wire orientation prior to cutting is to transition the endoscope from “short” to “long” position (Figure 5).    In         the            short    position,          the       endoscope       is         aligned along the lesser curvature of the stomach, in the long position the endoscope is aligned along the greater curvature of the stomach. Adjusting the endoscope position to the long position will typically correct an unacceptably rightward orientation and bring the cutting wire more into a more leftward, and hence safer, direction. If continued attempts at orienting the ampullary mound fail, one can also do a minimal biliary sphincterotomy followed by balloon sphincteroplasty.

Technique of Minimal Biliary

In some cases, one cannot make as long as a sphincterotomy as one would like. Anatomic causes of this situation include periampullary diverticulum, obscured ampullary landmarks, Billroth-II anatomy, or an extremely small papilla. Impaired coagulation causes include the patient actively taking anti-coagulants or anti-platelet agents which cannot be stopped, chronic renal failure, and hepatic cirrhosis with elevated INR not responsive to vitamin K replacement and/or thrombocytopenia. In these situations, mbES can be performed followed by balloon sphincteroplasty (Figure 6A, B, C,        D).       mbES  plus     balloon            sphincteroplasty         has an excellent safety record in regard to postprocedural bleeding, and still allows biliary therapy to be performed with a high degree of success. The mbES  is         quite            short    (about  2-3mm),          and      the       incision           very intentionally is not taken to its maximum. Dilation of         the       papillary         orifice is            accomplished  with a biliary balloon, the size of which is chosen to match the size of the distal CBD. An 8 or 10mm dilation balloon is most commonly used for biliary sphincteroplasty. The balloon is positioned across the           papillary            orifice and      2-3       mL      of         contrast           is         first     injected            into      the       balloon            to         facilitate         fluoroscopic            visualization.  Then    the       balloon            is         inflated           with            water to target diameter and held for 1-3 minutes, with longer dilation times favored for higher stone burden or larger diameter stones. The risk of a rare indication for pES. According to the Rome IV      criteria,           P-SOD can            be        defined            as         documented    episodes of recurrent acute pancreatitis, abnormal sphincter manometry study, and exclusion of other causes postbES bleeding is greatly lowered with the mbES technique.

Pancreatic Sphincterotomy Indications 

pES can be performed on both the major and minor papilla, depending on the indication for the procedure and ductal anatomy.22 Functional pancreatic    sphincter  of  Oddi disorder  (P-SOD)  is of pancreatitis such as alcohol, gallstones, medications, or metabolic derangements.14 There is a paucity of high-quality data regarding the efficacy  of pES for  P-SOD. A systematic review in 2006 revealed a

69% sustained symptomatic improvement from pES based on 5 non-randomized studies with 109 patients.23 Prospective studies have shown an almost 50% recurrence rate of acute pancreatitis, despite undergoing pES in the setting of P-SOD.24 Again, the entire concept of SOD is highly controversial and many centers have abandoned this notion.

A primary indication for pES is in the endoscopic management of chronic pancreatitis. Commonly, pES is utilized in conjunction with other endoscopic modalities such as pancreatic stricture dilation, balloon extraction of pancreatic stones, pancreatoscopy           and      pancreatic       duct     (PD)    stent placement to facilitate drainage and stricture remodeling.25 All of these are widely accepted indications for pES.

Pancreas divisum is a congenital condition resulting from an embryologic failure of fusion of the dorsal and ventral aspects of the pancreas. Acquired pancreas divisum can be seen in some cases of pancreatic duct obstruction in the head of the pancreas.27,28 In both situations, the majority of pancreatic drainage is via the pancreatic duct of Santorini and thence through the minor papilla.29 Pancreatic ductal obstruction in conjunction with minor papillary stenosis has been implicated in recurrent acute pancreatitis, chronic pancreatitis, and chronic pancreatic-type pain syndrome.30 Endoscopic mpES has been utilized for the management of pancreas divisum. An early study by           Lehman           et         al.        showed            a          significant benefit from    mpES in patients with recurrent acute pancreatitis in distinction to those with chronic pancreatitis or chronic pain.31 However, a 2012 literature review showed a widely variable range of symptomatic improvement after mpES, ranging from 58-92%.32 Contraindications to pancreatic sphincterotomy are similar to bES including uncontrolled coagulopathy or patient instability. Given the heightened risk of pancreatitis related to pES and mpES, these procedures should be performed by interventional endoscopists   with     a          significant       level    of training in pancreatic endoscopic therapy.

Major Papilla Pancreatic Sphincterotomy

The direction of pancreatic sphincterotomy at the major papilla is generally in the 12 to 1 o’clock direction. The length of the incision is different from biliary sphincterotomy because the PD dives deep into the retroperitoneal space as opposed to the case of the distal bile duct which has an intraduodenal segment prior to entering the retroperitoneal space.

Some         ERCP  specialists       find     it          easier  to         do        a pancreatic sphincterotomy after a previous biliary sphincterotomy, since the septum is exposed, and a more precise view of the pancreatic sphincter is available   (FIG    7A and      B).       The      septum is         incised a          few millimeters and the results examined.

One approach to pES is to cut a few millimeters, then push in the sphincterotome 1-2cm, halfbow the cutting wire, and then draw out the half-bowed sphincterotome. This is called the “sizing maneuver”. If a bowed sphincterotome can be pulled out with little resistance, then this can be considered as an adequate pancreatic sphincterotomy. If there is still resistance to pulling through a bowed sphincterotome, then the pES can be taken another 1-2mm, and the sizing maneuver repeated as needed. Excessive deep cutting of the PD sphincter may result in duodenal perforation.

Previous bES is not a requirement for doing pES, however. A pES can be performed with an intact biliary sphincter. The direction of the cut is 12 to 1 o’clock, and the sizing maneuver described above can be performed to estimate adequacy of the pES.

Another method of performing pES is needle knife incision over a previously placed pancreatic stent. In this technique, a needle knife incision is performed along the course of a PD stent. The procedure is somewhat easier after previous bES. The pancreatic sphincter can be visualized and cut with the needle knife. For pES over a PD stent, the sizing maneuver is not performed (since a bowingtype         sphincterotome  is not  employed).

Minor Papilla Pancreatic Sphincterotomy (mpES)

Minor papilla pancreatic sphincterotomy (mpES)  is performed in cases of pancreas divisum anatomy with recurrent acute pancreatitis, and on occasion for pancreatic endotherapy in non-divisum anatomy, but with a completed obstructed main PD of the duct of Wirsung (“acquired pancreas divisum”).28    Like     pES     at         the       major  papilla, mpES can be performed with either a bowing sphincterotome, or with a needle knife over a previously placed PD stent. Also similar to pES at the major papilla, stepwise incisions are performed with a bowing sphincterotome, or a needle knife over a previously placed PD stent. The sizing maneuver is also possible at the minor papilla if the bowing sphincterotome is used. In some cases of divisum, particularly in acquired    divisum,          the       orifice of         the       minor  papilla may be quite stenotic, and although a guidewire can be advanced into the dorsal PD, a sphincterotome cannot           be        advanced         through           the       tight            orifice, making            correct placement of the cutting wire impossible. In these rare cases, a needle-knife sphincterotomy can be performed using the guidewire as a guide. This can open the sphincter enough to eventually get either a bowing sphincterotome into position, or to place a 4 or 5 French pancreatic stent, over which a needle knife mpES can be performed.

Transpancreatic Biliary Sphincterotomy for Biliary Access

A technique has been described by Goff describing biliary access after performing a limited pancreatic sphincterotomy.33 This technique may be applied if there is difficulty obtaining selective access  to the bile duct. In this situation, the guidewire has been deeply inserted into the main pancreatic duct, and the bowing sphincterotome is used to make a somewhat pancreatic sphincterotomy while pulling the sphincterotome in a biliary direction i.e. towards 11 o’clock. This often will open the distal bile duct, which can then be cannulated with the      assistance        of a          floppy wire.    The endoscopist     may elect to place a temporary pancreatic stent (for example, 4 French x 11cm)  after    this      access maneuver, but this is not universally performed.

Needle Knife Biliary Sphincterotomy (NKS) and Needle Knife Fistulotomy (NKF)

Needle knife biliary sphincterotomy is an essential tool for all ERCP specialists. The ability to perform the NKS technique can greatly increase the rate of successful deep biliary cannulation in patients who have failed prior cannulation attempts with standard techniques. NKS is typically used in cases of failed biliary deep cannulation, although it may be used as a primary technique in ampullae that contain an impacted stone, or when the papillary orifice is pointing   in an unfavorable direction.  There is a related technique, called needle knife fistulotomy     (NKF), in  which  the  initial  site  of  cutting is  above, rather  than  at,  the  papillary orifice (Figure 8). Some   practitioners   favor   NKF    over     NKS because of a belief that this can lower the incidence of post-ERCP      pancreatitis (PEP). Emerging        data     suggests that NKS or NKF-associated PEP may be more related to previous unsuccessful cannulation attempts rather than the NKS itself. The authors prefer NKS in most situations, reserving NKF in cases of very bulging ampullae or in situations where  the papillary orifice is not easily  found   or standard tools cannot be properly oriented.

The technique of NKS and NKF is the same, differing only in the initial site of initiation of the incision. For both techniques, a long mucosal incision is carried out in the same direction as a standard wire guided sphincterotome performed with a bowing sphincterotome. The cut is taken in the 11-12 o’clock direction until most of the mucosa overlying the intraduodenal mound is incised. In some cases of a very bulging ampulla, the initial incision may gain access to the bile duct, and this event is heralded by a large discharge of bile. More commonly, however, the technique of NKS is a two-step process: initial mucosal incision followed      by        identification  and      cutting into      the exposed intraduodenal bile duct (the “Huibregtse technique”).

The initial mucosal incision should be long enough to expose the underlying biliary structures in the intraduodenal segment. After the initial mucosal incision is made, the edges of the cut can be seen to retract laterally, exposing the inner structures. We have found that success is more predictably achieved by taking a “visual approach” to identifying the bile duct after adequate initial mucosal incision. The needle knife device is used to make a vertical incision into a tubular structure that might be found. This tubular structure typically is white or tan in colon with a “matte” rather      than glossy  surface (Figure 9).        In         cases   of         non-dilated distal bile ducts (for example, with malignant        biliary obstruction),   the       intraduodenal  bile duct is quite narrow, and visualization may be challenging. Making stepwise vertical incisions followed by gentle probing with the guidewire in the presumed biliary direction will often allow biliary access. If not, repeating some more short vertical incisions followed by more gentle probing with the guidewire is the next step. In some cases, despite repeated incisions and probing, deep biliary cannulation cannot be achieved. In such cases, it may be reasonable to stop cannulation attempts, and bring the patient back on a different day for a repeat attempt at biliary access. At the time of repeat   ERCP, the biliary orifice is         often    obvious,          and cannulation is achieved promptly. If the biliary endoscopist is comfortable with NKS, it is important to not over-persist with regular cannulation attempts before changing to NKS. One reason for this is that persistence can increase the risk of PEP. Another reason is that persistent cannulation attempts prior to NKS can actually decrease the success rate of subsequent successful NKS. This appears to be due to tissue edema or even inadvertent submucosal injections which obscures the submucosal structures after initial incision.

NKS can be performed as a “freehand” procedure or can be performed following placement of a pancreatic duct stent. Both techniques are reasonable and in experienced hands, safe.

Adverse Events Related to Endoscopic Sphincterotomy

It is paramount for an endoscopist performing ERCP to be familiar with adverse events associated with NKS, to take necessary preventative steps, and to promptly recognize and manage any adverse events that do arise.34 Post-sphincterotomy hemorrhage (PSH) occurs at a rate of 1-48%.35 PSH     is            defined according to timing and severity.  Immediate PSH occurs during the index ERCP, while delayed PSH can occur hours to days later.5,35 Cotton et al. described mild PSH as clinical evidence of bleeding with less than  3  gm/dL drop in  hemoglobin without need for transfusion, moderate PSH as requiring less than 4 units of packed red blood cells without need for angiography or surgery, and severe PSH as requiring 5 units or more of packed red blood cells or the need for angiographic or surgical intervention.5,35 In practice, however, any PSH that requires blood transfusion is considered to be           significant. Freeman et al.’s landmark study8 found that definite risk factors for PSH     are       pre-procedural coagulopathy, use of anti-coagulants within 3 days of performing ES, ascending cholangitis as an indication for ERCP, immediate bleeding during initial ES, and low endoscopic case volumes on the part of the sphincterotomy. The tissue effect that one is looking      for       (aside  from            cessation         of         bleeding)         is         creation of a submucosal “bleb” with injection. Use of a metal sheath injection needle (CarrLocke   injection            needle, Steris,  Mentor OH)     is         advantageous as there is less likelihood that the needle sheath will deform or “kink” as compared with plastic sheathed needles.

Thermal therapy to treat bleeding with bipolar cautery, monopolar cautery, argon plasma coagulation, and hemostatic clips have been used for control of PSH.35,38 However, manipulation of clips or stiff hemostasis probes can be quite challenging through a duodenoscope. More recently, placement of fully covered self-expanding metal stents has been shown to treat PSH by creating a tamponade effect on the sphincterotomy site. Stent placement is highly  efficacious as both a primary modality for PSH or as a rescue therapy when other therapies fail.39,40 A feared complication of ES is perforation, the incidence of which is approximately 1% based on older data, but is probably much less in the current era.41        A classification  of ERCP-related  perforations was proposed by Stapfer et al.42 Type I injury is duodenal wall trauma from the duodenoscope and is typically located on the duodenal wall

opposite to the ampulla. Type II injury is a periampullary perforation related to ES and is the most common type ranging from 15-68% of cases.43 Type III injuries are ductal in location and related to instrumentation such as wire perforation. Type IV injury represents retroperitoneal air alone.

Patient-related factors for sphincterotomy perforation    are       biliary sphincter disorder           (SOD) and      a dilated common bile duct. Procedural related risk factors are performing a pre-cut sphincterotomy and longer sphincterotomy length.44 Retroperitoneal perforations can be graded based on the consensus definition        by Cotton et         al.:       mild    is         low      volume            leakage of contrast with medical treatment less than 3 days, moderate is with medical treatment 4-10 days, and severe is medical treatment lasting longer than 10 days with possible percutaneous or surgical intervention.5 In common practice, the Cotton classification  is no longer  used.               

Prompt recognition of a perforation is of utmost importance to minimize leakage of enteral contents into the retroperitoneal space. The use of carbon dioxide   insufflation is         essential          when   performing      ERCP  (Figure 10)       as         this      has been    shown  to         be        associated with less pain, abdominal distention, and adverse events.45,46 Medical management of a perforation includes supportive care, bowel rest, and intravenous antibiotics.47 There is limited evidence for the use of endoscopic clips for the closure of sphincterotomy related perforations.48,49 When a peri-ampullary perforation is recognized, immediate diversion of biliary contents should be initiated by placing a biliary stent, or on rare occasions a nasobiliary drain.50 Surgical management is required when patients do not respond to medical and endoscopic modalities or when the presentation is delayed and there is  significant retroperitoneal contamination.50 Fortunately, surgery is rarely required in these situations. Post-ERCP  pancreatitis (PEP)51,52 has been associated with biliary and pancreatic sphincterotomy. The likelihood of developing PEP is related to a combination of operator, patient, and procedural related factors and the contribution of sphincterotomy itself is unclear. For example, although NKS has been implicated in the development of PEP, this may be due to the delayed use of this technique resulting in multiple failed cannulation attempts rather than the NKS itself.53 In a systematic review and meta-analysis of randomized controlled trials, early pre-cut NKS did not increase the risk for pancreatitis.54 The management of acute post-ERCP pancreatitis is comparable with other etiologies of acute pancreatitis.

Other reported complications of endoscopic biliary sphincterotomy are ascending cholangitis and delayed papillary stenosis.8,55 Papillary stenosis of   the       biliary orifice after    ES       can      result   in         biliary symptoms and choledocholithiasis.56 There do not    appear to         be        any      significant long-term        biliary problems, including the development of biliary malignancy, in patients that have undergone biliary sphincterotomy, even more than 25 years later. Patients who have undergone biliary sphincterotomy and have intact gallbladders are at risk for later acute cholecystitis, probably due to bacterial access to the gallbladder, but only if gallbladder stones are present. The            complication   rate      specifically     for       pES     is            approximately 10%.57 Recurrent acute pancreatitis may be a complication related to post-ES pancreatic papillary stenosis.25

Training and Competency in Endoscopic Sphincterotomy

Competency in bES requires formal training and an adequate number of supervised procedures. Most gastroenterology trainees will not attain this level of competency during their general gastroenterology fellowship and an additional year of advanced endoscopic training is optimal.58 The minimum number of procedures for independent practice will vary depending on the exposure and individual skill of the trainee, however, there have been standards proposed by various endoscopy organizations.

As per the ASGE, a minimum of 200 proctored ERCP procedures and 80 biliary sphincterotomies should be performed prior to independent practice.59 The European Society for Gastrointestinal Endoscopy and the UK Joint Advisory Group both suggest a minimum of 300 proctored ERCP examinations during training, however, neither group specifies the number of bES needed for independent practice.60,61 Finally, the Canadian Association for Gastroenterology recommends a minimum of 200 supervised ERCP procedures with 80 biliary sphincterotomies performed in the training setting.62

Despite the published standards for bES training, the true minimum number needed for competency remains unclear. A 2019 multi-center cohort study involving 32 advanced endoscopy programs in the United States reported that 120 bES are required for competency based on a standardized assessment tool.63 However, a prior study by the same authors in 2016 revealed a broad range of case numbers needed to attain competency in basic ERCP skills. Furthermore, none of the trainees in this study were determined to be proficient in bES, thus contributing to the lack of clarity on training metrics for this subject.64 Pre-cut needle-knife sphincterotomy (NKS), needle-knife fistulotomy (NKF), and trans-pancreatic sphincterotomy (TPS) are important skills for the “full service” ERCP specialist.65 Despite numerous studies assuring the safety and efficacy of these techniques, the learning curve is less well studied.65-67 For NKS, the reported learning curve has been widely variable, ranging from 13 to 100 cases for competence.68,69 Similarly, for NKF there is a wide reported range of cases from 20 to 100 prior to gaining mastery.70,71 For performance of pancreatic endotherapy, mastery of pES is an important skill for an ERCP specialist. However, there are no standardized guidelines regarding gaining competency for pES. Therefore, it is preferable for pES to be performed by endoscopists with specialized training in pancreatic endoscopic therapy.

CONCLUSION

ES is a vital tool for all interventional endoscopists who plan to perform ERCP with biliary and pancreatic interventions. One must be wellinformed on the accepted indications and adverse events related to this procedure. An advanced endoscopist must be skilled at treating complications related to ES. Furthermore, additional endoscopic training to perform ES should be pursued prior to independent practice, ideally in the setting of a formal advanced endoscopy training program. Additionally, one must understand when an ES in not technically feasible due to medical and anatomic considerations. 

The minimal sphincterotomy plus papillary balloon dilation technique is very important in cases when biliary sphincterotomy is necessary, but the patient has an uncorrectable coagulopathy, is concurrently using of anticoagulant or antiplatelet medications, or has anatomic constraints to full sphincterotomy. When traditional access to the bile or pancreatic ducts is not technically feasible, it is imperative that one is skilled in the use of pre-cut ES techniques such as NKS to help facilitate cannulation. Pancreatic sphincterotomy of the major or minor papilla is also an important technique but should be restricted to ERCP practitioners with special expertise in pancreatic endotherapy.

References

  1. McCune WS, Shorb PE, Moscovitz H. Endoscopic cannulation of the ampulla of Vater: a preliminary report. Ann Surg 1968;167:752–756.
  2. Kawai K, Akasaka Y, Murakami K, Tada M, Koli Y. Endoscopic sphincterotomy of the ampulla of Vater. Gastrointest Endosc 1974;20:148–151.
  3. Classen M, Demling L. Endoskopische Sphinkterotomie der Papilla Vateri und Steinextraktion aus dem Ductus choledochus. Dtsch Med Wochenschr 1974;99:496–497.
  4. Adler DG, Baron TH, Davila RE, et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas.
    Gastrointest Endosc. 2005;62(1):1-8. doi:10.1016/j. gie.2005.04.015
  5. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37(3):383393. doi:10.1016/s0016-5107(91)70740-2
  6. Dumonceau JM, Kapral C, Aabakken L, et al. ERCPrelated adverse events: European Society of Gastrointestinal
    Endoscopy (ESGE) Guideline. Endoscopy. 2020;52(2):127-149. doi:10.1055/a-1075-4080
  7. Köksal AŞ, Eminler AT, Parlak E. Biliary endoscopic sphincterotomy: Techniques and complications. World J Clin Cases. 2018;6(16):1073-1086. doi:10.12998/wjcc.v6.i16.1073
  8. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996;335(13):909-918. doi:10.1056/ NEJM199609263351301
  9. Ryozawa S, Itoi T, Katanuma A, et al. Japan Gastroenterological Endoscopy Society guidelines for endoscopic sphincterotomy. Dig Endosc. 2018;30(2):149-173. doi:10.1111/den.13001
  10. Minami A, Hirose S, Nomoto T, Hayakawa S. Small sphincterotomy combined with papillary dilation with large balloon permits retrieval of large stones without mechanical lithotripsy. World J Gastroenterol. 2007;13(15):2179-2182. doi:10.3748/wjg.v13.i15.2179
  11. Kaffes AJ, Hourigan L, Luca ND, Byth K, Williams SJ, Bourke MJ. Impact of endoscopic intervention in 100 patients with suspected postcholecystectomy bile leak. Gastrointest Endosc. 2005;61(2):269-275. doi:10.1016/S0016-5107(04)02468-X
  12. Davids PH, Rauws EA, Tytgat GN, Huibregtse K. Postoperative bile leakage: endoscopic management. Gut. 1992;33(8):1118-1122. doi:10.1136/gut.33.8.1118
  13. Cotton PB, Durkalski V, Romagnuolo J, et al. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial. JAMA. 2014;311(20):2101. doi:10.1001/jama.2014.5220
  14. Cotton PB, Elta GH, Carter CR, Pasricha PJ, Corazziari ES. Rome IV. Gallbladder and sphincter of Oddi disorders.
    Gastroenterology. 2016;150:1420-1429. doi:10.1053/j.gastro.2016.02.033
  15. Dayyeh BKA, Baron TH. Endoscopic sphincterotomy: Indications, techniques, and adverse events. Tech Innov Gastrointest Endosc. 2019;0(0). doi:10.1016/j.tgie.2012.04.001
  16. Acosta RD, Abraham NS, Chandrasekhara V, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016;83(1):3-16. doi:10.1016/j.gie.2015.09.035
  17. Mok SRS, Arif M, Diehl DL, Khara HS, Ho HC, Elfant AB. Safety and efficacy of minimal biliary sphincterotomy with papillary balloon dilation (m-EBS+EPBD) in patients using clopidogrel or anticoagulation. Endosc Int Open. 2017;5(3):E157-E164. doi:10.1055/s-0042-120225
  18. Srinivasan I, Freeman ML. Guidewire trauma: a key component of post-ERCP pancreatitis that is best controlled by the endoscopist. Am J Gastro. 2016 1;111:1848-50.
  19. Huibregtse K, Katon RM, Tytgat GN. Precut papillotomy via fine-needle knife papillotome: a safe and effective technique. Gastrointest Endosc. 1986 Dec 1;32(6):403-5.
  20. Mu P, Yue P, Li F, Lin Y, Liu Y, Meng W, Zhou W, Li X. Does periampullary diverticulum affect ERCP cannulation and post-procedure complications? An up-to-date metaanalysis. The Turk J Gastro. 2020 Mar;31(3):193.
  21. Seibert DG, Matulis SR. Consistent improvement in sphincterotome orientation with manual grooming. Gastrointest Endosc. 1995;42(4):325-9.
  22. Sherman S, Lehman GA. Endoscopic pancreatic sphincterotomy: techniques and complications. Gastrointest Endosc Clin N Am. 1998;8(1):115-124.
  23. Sgouros SN, Pereira SP. Systematic review: sphincter of Oddi dysfunction – non-invasive diagnostic methods and long-term outcome after endoscopic sphincterotomy – Aliment Pharm and Therap. 2006;24:237-246
  24. Coté GA, Imperiale TF, Schmidt SE, et al. Similar efficacies of biliary, with or without pancreatic, sphincterotomy in treatment of idiopathic recurrent acute pancreatitis. Gastroenterology. 2012;143(6):1502-1509.e1. doi:10.1053/j. gastro.2012.09.006
  25. Buscaglia JM. Pancreatic sphincterotomy: Technique, indications, and complications. World J Gastroenterol. 2007;13(30):4064. doi:10.3748/wjg.v13.i30.4064
  26. Mashiana HS, Dhaliwal AS, Sayles H, et al. Endoscopic retrograde cholangiopancreatography in cirrhosis – a systematic review and meta-analysis focused on adverse events. World J Gastrointest Endosc. 2018;10(11):354-366. doi:10.4253/wjge.v10.i11.354
  27. Cotton PB. Congenital anomaly of pancreas divisum as cause of obstructive pain and pancreatitis. Gut. 1980;21(2):105-doi:10.1136/gut.21.2.105
  28. Warshaw AL, Cambria RP. False pancreas divisum. Acquired pancreatic duct obstruction simulating the congenital anomaly. Ann Surg. 1984;200(5):595-599. doi:10.1097/00000658-198411000-00007
  29. Michailidis L, Aslam B, Grigorian A, Mardini H. The efficacy of endoscopic therapy for pancreas divisum: a meta-analysis. Ann Gastroenterol. 2017;30(5):550-558. doi:10.20524/aog.2017.0159
  30. M Delhaye CM, re. Pancreatic ductal system obstruction and acute recurrent pancreatitis. World J Gastroenterol. 2008;14(7):1027-1033. doi:10.3748/wjg.14.1027
  31. Lehman GA, Sherman S, Nisi R, Hawes RH. Pancreas divisum: results of minor papilla sphincterotomy. Gastrointest Endosc. 1993;39(1):1-8. doi:10.1016/s0016-5107(93)70001-2
  32. Fujimori N, Igarashi H, Asou A, et al. Endoscopic approach through the minor papilla for the management of pancreatic diseases. World J Gastrointest Endosc. 2013;5(3):81-88.
  33. Goff JS. Long-term experience with the transpancreatic sphincter pre-cut approach to biliary sphincterotomy. Gastrointest Endosc. 1999 Nov 1;50(5):642-5.
  34. Chandrasekhara V, Khashab MA, Muthusamy VR, et al. Adverse events associated with ERCP. Gastrointest Endosc. 2017;85(1):32-47. doi:10.1016/j.gie.2016.06.051
  35. Ferreira LEVVC, Baron TH. Post-sphincterotomy bleeding: who, what, when, and how. Am J Gastro. 2007;102(12):28502858.
  36. Wilcox CM, Canakis J, Mönkemüller KE, Bondora AW, Geels W. Patterns of bleeding after endoscopic sphincterotomy, the subsequent risk of bleeding, and the role of epinephrine injection. Am J Gastroenterol. 2004;99(2):244-248. doi:10.1111/j.1572-0241.2004.04058.x
  37. Leung JWC, Chan FKL, Sung JJY, Chung SCS. Endoscopic sphincterotomy-induced hemorrhage: A study of risk factors and the role of epinephrine injection. Gastrointest Endosc. 1995;42(6):550-554. doi:10.1016/S0016-5107(95)70009-9
  38. Baron TH, Norton ID, Herman L. Endoscopic hemoclip placement for post-sphincterotomy bleeding. Gastrointest Endosc. 2000;52(5):662.doi:10.1067/mge.2000.108621
  39. Cochrane J, Schlepp G. Comparing endoscopic intervention against fully covered self-expanding metal stent placement for post-endoscopic sphincterotomy bleed (CEASE Study). Endosc Int Open. 2016;04(12):E1261-E1264. doi:10.1055/s-0042-118227
  40. Canena J, Liberato M, Horta D, Romão C, Coutinho A. Short-term stenting using fully covered self-expandable metal stents for treatment of refractory biliary leaks, postsphincterotomy bleeding, and perforations. Surg Endosc. 2013;27(1):313-324. doi:10.1007/s00464-012-2368-3
  41. Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP: a prospective study. Gastrointest Endosc.2004;60(5):721-731. doi:10.1016/s0016-5107(04)02169-8
  42. Stapfer M, Selby RR, Stain SC, et al. Management of duodenal perforation after endoscopic retrograde cholangiopancreatography and sphincterotomy. Ann Surg.
    2000;232(2):191-198. doi:10.1097/00000658-200008000-00007
  43. Trikudanathan G, Hoversten P, Arain M, Attam R, Freeman M, Amateau S. The use of fully-covered selfexpanding metallic stents for intraprocedural management of post-sphincterotomy perforations: a single-center study (with video). Endosc Int Open. 2018;06(01):E73-E77. doi:10.1055/s-0043-121884
  44. Enns R, Eloubeidi MA, Mergener K, et al. ERCP-related perforations: risk factors and management. Endoscopy. 2002;34(4):293-298. doi:10.1055/s-2002-23650
  45. Bretthauer M, Seip B, Aasen S, Kordal M, Hoff G, Aabakken L. Carbon dioxide insufflation for more comfortable endoscopic retrograde cholangiopancreatography: a randomized, controlled, double-blind trial. Endoscopy. 2007;39(01):58-64. doi:10.1055/s-2006-945036
  46. Lee JH, Kedia P, Stavropoulos SN, Carr-Locke D. AGA Clinical Practice Update on Endoscopic Management of Perforations in Gastrointestinal Tract: Expert Review. Clin Gastroenterol Hepatol. 2021;19(11):2252-2261.e2. doi:10.1016/j.cgh.2021.06.045
  47. Kumbhari V, Sinha A, Reddy A, et al. Algorithm for the management of ERCP-related perforations. Gastrointest Endosc. 2016;83(5):934-943. doi:10.1016/j.gie.2015.09.039
  48. Katsinelos P, Paroutoglou G, Papaziogas B, Beltsis A, Dimiropoulos S, Atmatzidis K. Treatment of a duodenal perforation secondary to an endoscopic sphincterotomy with clips. World J Gastroenterol. 2005;11(39):6232-6234. doi:10.3748/wjg.v11.i39.6232
  49. Baron TH, Gostout CJ, Herman L. Hemoclip repair of a sphincterotomy-induced duodenal perforation. Gastrointest Endosc. 2000;52(4):566-568. doi:10.1016/S0016-5107(00)70032-0
  50. Howard TJ, Tan T, Lehman GA, et al. Classification and management of perforations complicating endoscopic sphincterotomy. Surgery. 1999;126(4):658-665. doi:10.1016/ S0039-6060(99)70119-4
  51. Cheng CL, Sherman S, Watkins JL, et al. Risk Factors for Post-ERCP Pancreatitis: A Prospective Multicenter Study. Am J Gastroenterol. 2006;101(1):139-147. doi:10.1111/ j.1572-0241.2006.00380.x
  52. Chen JJ, Wang XM, Liu XQ, et al. Risk factors for postERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years. Eur J Med Res. 2014;19(1):26. doi:10.1186/2047-783X-19-26
  53. Bailey AA, Bourke MJ, Kaffes AJ, Byth K, Lee EY, Williams SJ. Needle-knife sphincterotomy: factors predicting its use and the relationship with post-ERCP pancreatitis (with video). Gastrointest Endosc. 2010;71(2):266-271. doi:10.1016/j.gie.2009.09.024
  54. Sundaralingam P, Masson P, Bourke MJ. Early precut sphincterotomy does not increase risk during endoscopic retrograde cholangiopancreatography in patients with difficult biliary access: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2015;13(10):1722-1729. e2. doi:10.1016/j.cgh.2015.06.035
  55. Rösch W, Riemann JF, Lux G, Lindner HG. Long-term follow-up after endoscopic sphincterotomy. Endoscopy. 1981;13(04):152-153. doi:10.1055/s-2007-1021671
  56. Prat F, Malak NA, Pelletier G, et al. Biliary symptoms and complications more than 8 years after endoscopic sphincterotomy for choledocholithiasis. Gastroenterology.
    1996;110(3):894-899. doi:10.1053/gast.1996.v110. pm8608900
  57. Asbun HJ, Rossi RL, Heiss FW, Shea JA. Acute relapsing pancreatitis as a complication of papillary stenosis after endoscopic sphincterotomy. Gastroenterology.
    1 9 9 3 ; 1 0 4 ( 6 ) : 1 8 1 4 – 1 8 1 7 . d o i : 1 0 . 1 0 1 6 / 0 0 1 6 -5085(93)90663-w
  58. Wani S, Keswani RN, Petersen B, et al. Training in EUS and ERCP: standardizing methods to assess competence.
    Gastrointest Endosc. 2018;87(6):1371-1382. doi:10.1016/j. gie.2018.02.009
  59. Faulx AL, Lightdale JR, Acosta RD, et al. Guidelines for privileging, credentialing, and proctoring to perform GI endoscopy. Gastrointest Endosc. 2017;85(2):273-281. doi:10.1016/j.gie.2016.10.036
  60. Johnson G, Webster G, Boškoski I, et al. Curriculum for ERCP and endoscopic ultrasound training in Europe: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2021;53(10):1071-1087. doi:10.1055/a-1537-8999
  61. Siau K, Keane MG, Steed H, et al. UK Joint Advisory Group consensus statements for training and certification in endoscopic retrograde cholangiopancreatography. Endosc Int Open. 2022;10(1):E37-E49. doi:10.1055/a-1629-7540
  62. Springer J, Enns R, Romagnuolo J, Ponich T, Barkun AN, Armstrong D. Canadian credentialing guidelines for endoscopic retrograde cholangiopancreatography. Can J Gastroenterol J Can Gastroenterol. 2008;22(6):547-551. doi:10.1155/2008/582787
  63. Wani S, Han S, Simon V, et al. Setting minimum standards for training in EUS and ERCP: results from a prospective multicenter study evaluating learning curves and competence among advanced endoscopy trainees. Gastrointest Endosc. 2019;89(6):1160-1168.e9. doi:10.1016/j.gie.2019.01.030
  64. Wani S, Hall M, Wang AY, et al. Variation in learning curves and competence for ERCP among advanced endoscopy trainees by using cumulative sum analysis.
    Gastrointest Endosc. 2016;83(4):711-719.e11. doi:10.1016/j. gie.2015.10.022
  65. Swan MP, Alexander S, Moss A, Williams SJ, Ruppin D, Hope R, Bourke MJ. Needle knife sphincterotomy does not increase the risk of pancreatitis in patients with difficult biliary cannulation. Clin Gastroenterol Hepatol. 2013;11(4):430-436.e1. doi:10.1016/j.cgh.2012.12.017
  66. Pécsi D, Farkas N, Hegyi P, et al. Transpancreatic sphincterotomy has a higher cannulation success rate than needle-knife precut papillotomy – a meta-analysis. Endoscopy. 2017;49(9):874-887. doi:10.1055/s-0043-111717
  67. Lim JU, Joo KR, Cha JM, et al. Early use of needle-knife fistulotomy is safe in situations where difficult biliary cannulation is expected. Dig Dis Sci. 2012;57(5):1384-1390. doi:10.1007/s10620-012-2030-x
  68. Li JW, Ang TL, Kam JW, Kwek ABE, Teo EK. The learning curve for needle knife precut sphincterotomy revisited. United Eur Gastroenterol J. 2017;5(8):1116-1122. doi:10.1177/2050640617701808
  69. Akaraviputh T, Lohsiriwat V, Swangsri J, Methasate A, Leelakusolvong S, Lertakayamanee N. The learning curve for safety and success of precut sphincterotomy for therapeutic ERCP: a single endoscopist’s experience. Endoscopy. 2008;40(6):513-516. doi:10.1055/s-2007-995652
  70. Lopes L, Dinis-Ribeiro M, Rolanda C. Gaining competence in needle-knife fistulotomy – can I begin on my own? Endosc Int Open. 2016;04(04):E383-E388. doi:10.1055/s-0041-109399
  71. Fernandes J, Canena J, Alexandrino G, et al. Outcomes of single-endoscopist-performed needle-knife fistulotomy for selective biliary access in 842 consecutive patients: learning curve and changes over a 14-year period in a retrospective study. Scand J Gastroenterol. 2021;56(11):1363-1370.doi:10.1080/00365521.2021.1958369

Download Tables, Images & References

NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #228

Nutrition Issues in Gastroenterology : A Tale of Two Decades

Read Article

Well, it’s time to hang up my nutrition series editor spurs this December 2022. To say it has been an honor and a privilege to be the nutrition series editor for Practical Gastroenterology the past 20 years would be quite an understatement.

First, I must thank Dr. David Peura for suggesting me for the position so many years ago, as well as encouraging me to take it on. Second, it was my very good fortune to have had Dorine Kitay as the editor above me for many years, who also became my very dear friend. After Dorine retired, Vivian Mahl and her sister Adrien took over, and along with James Green, these three have been a fun, supportive, and professional team to work with. The series has not only enriched my professional career, but also enhanced my own clinical practice immeasurably; I learned something from each author that I could take back to the bedside. It has been a pleasure to work with so many gifted clinicians and writers over the years from around the globe, generously sharing their clinical and intellectual expertise with the readers of this series.

Many doors were opened to me following publication of articles in the series. The articles led to invitations to present at the regional, state, national, and international levels. I have been an expert witness more than once because of an article written for this series (although I must admit, it is not something I enjoy, as someone invariably loses, and the “Pollyanna” in me is saddened by that). Desperate patients or their families and friends have contacted me (usually calling me at home on a Friday night or weekend afternoon), frantic for help for a loved one suffering from a particular condition that was covered in a published article – it has been very humbling to say the least. 

To the authors who have written for me, I thank you for making this series such a success; it would not have been possible without you! The same goes for the many various clinicians who have given of their time and sage advice in reviewing the articles over the years. And I would be remiss if I did not mention my wonderful husband, a gifted writer in his profession as an attorney, who has proofed more than one paragraph or two over these many years. Finally, I want to thank the readers of this series, and the clinicians who have contacted me, or approached me at conferences, just to express their gratitude for the nutrition series and to tell me that the articles have been helpful in the care of their patients—that is what kept me going for so long. A compilation of the entire series from January 2003 to December 2022 can be found on-line for the time being at: ginutrition.virginia.edu (see titles of entire series below in Table 1); the series from 2014 onward can also be found at the Practical Gastroenterology website at: practicalgastro.com.

Changing of the Guard

I am delighted to introduce the two incoming nutrition series co-editors who will begin the new nutrition series in the journal, “Nutrition Reviews in Gastroenterology.

Please welcome:

Elizabeth Wall, MS, RDN-AP, CNSC, LDN

Elizabeth Wall has been an Advanced Clinical Specialist on the Adult GI/Nutrition Support Service at The University of Chicago Medicine for the past 35 years. She earned a Bachelor of Science degree in Dietetics from the University of Illinois at Urbana-Champaign, a Master of Science degree in Human Nutrition and Nutritional Biology from the University of Chicago and completed a dietetic internship at the Massachusetts General Hospital. Elizabeth’s scope of clinical practice includes management of patients who require short and long term enteral and parenteral nutrition support, as well as the provision of medical nutrition therapies for patients with inflammatory bowel disease, malabsorptive disorders, and short bowel syndrome/intestinal failure. In addition to her clinical responsibilities, Elizabeth is an active participant in human research protocols and has served as a faculty member at DePaul University and the Dietitians in Nutrition Support’s Advance Practice Residency. She is a member of the Academy of Nutrition and Dietetics, the American Society for Parenteral and Enteral Nutrition, and is active in national and international professional workgroups related to short bowel syndrome/intestinal failure. Elizabeth is the author of many book chapters, peer reviewed articles, and has presented on many GI/ nutrition support related topics at local, national, and international symposia.

Neha D. Shah MPH, RD, CNSC, CHES

Neha has been specializing in nutrition for GI disorders for over 15 years. She started her career as an inpatient dietitian at Stanford Health Care, counseling patients at the bedside while they recovered from gastrointestinal surgery. She later joined the Stanford Digestive Health Center to inaugurate and build Nutrition Services for the GI and Liver Clinics. There, she co-led the development of the outpatient Nutrition Support and Intestinal Rehabilitation programs to streamline specialized care to those on home nutrition support and those with short bowel syndrome. She also served as the Intestinal Transplant dietitian to provide pre-and post-transplant care. She is now at the University of California, San Francisco, specializing in GI, IBD, and intestinal rehabilitation. Neha also owns a GI and liver nutrition private practice, Neha Shah Nutrition, to bring specialized nutrition care to the community. In addition to patient care, Neha has authored over 20 articles in reputable journals related to GI nutrition. To highlight some of her roles in professional organizations, she is Director of Operations and Treasurer of the International South Asian IBD Alliance and is a member of the Crohn’s and Colitis Medical Advisory Committee of Northern California. Her goal is to continue to be involved with GI initiatives, including writing and publishing articles to move nutrition care forward in this patient population. As you can see, the new nutrition series will be in good and capable hands.

Download Tables, Images & References

Jojobet GirişmatbetcasibommeritkingcasibomcasibomcasibomGrandpashabetgrandpashabetcasibomGrandpashabetzirvebetjojobetcasibomGrandpashabetGrandpashabetGrandpashabetgrandpashabetcasibombetpasjojobet girişjojobet güncel girişUltrabetjojobetmatbetdeneme bonusu veren sitelerdeneme bonusu veren sitelermadridbetmadridbetMadridbetMadridbetgrandpashabetHoliganbet girişcasibomgrandpashabet girişJojobetcasibomgrandpashabetjojobetcasibomjojobetjojobetgrandpashabet girişcasibombetciograndpashabet girişcasibom girişgrandpashabet girişgrandpashabetgrandpashabetholiganbetBetpas